

LUNG FUNCTION TESTING: SELECTION OF REFERENCE VALUES AND INTERPRETATIVE STRATEGIES

THIS OFFICIAL STATEMENT OF THE AMERICAN THORACIC SOCIETY WAS ADOPTED BY THE ATS BOARD OF DIRECTORS, MARCH 1991.

Contents

- Introduction
 - Background
 - Focus
- Sources of Variation in Lung Function Testing
 - Conceptual issues pertinent to the interpretation of lung function tests
 - Technical sources of variation
 - Procedural sources of variation
 - Biologic sources of variation
- Statistical Considerations in the Derivation of Prediction Equations
 - General comments
 - Characterizing the distribution and determinants of lung function in reference populations
 - Evaluating prediction equations
 - Distributions and "lower limits of normal"
- Sources, Uses, and Selection of Reference Values
 - General comments
 - Sources of reference equations
 - Determination of the "normal range"
 - Smoking as an independent variable
 - Cross-sectional and longitudinal predictions
 - Criteria for selection of reference values
 - Published reference equations
 - Limitations of currently available equations
- Interpretative Strategies
 - Conceptual issues concerning normality and the limits of normal
 - Obstructive and restrictive ventilatory defects
 - Bronchodilator response
 - Interpretation of lung function tests in clinical practice
- Recommendations
 - Overall
 - Selecting reference values
 - Recommendations for interpretation

Introduction

Background

During the last 3 decades lung function tests have evolved from tools for physiologic study to clinical tools widely used in assessing respiratory status. In addition to their use in

clinical case management, they have become a part of routine health examinations in respiratory, occupational, and sports medicine and in public health screening. It is common practice for the results of lung function tests to be interpreted in relation to reference values, and in terms of whether or not they are considered to be within the "normal" range (1-6). A wide selection of published reference values and "lower limits of normal" is available (4). Computerized equipment adds a new dimension with preselected or menus of reference values and interpretation algorithms whose origin and justification may be unclear.

To maximize the clinical value of lung function tests and to assist those managing clinical lung function testing laboratories, the American Thoracic Society (ATS) (7-12), the European Community for Coal and Steel (ECCS) (4), and the European Society for Clinical Respiratory Physiology (13) have published guidelines, focusing primarily on spirometry as the most widely used lung function test. The 1987 ATS statement in spirometry (8) outlined the steps necessary to achieve standardization: (1) equipment performance, validation, and quality control; (2) subject performance; (3) measurement procedures to determine acceptability and reproducibility; (4) reference values and interpretation. The first three have been addressed in official statements or position papers of the ATS (7-12). This statement addresses the fourth.

Focus

The charge by the ATS was to prepare a comprehensive and practical document dealing with conceptual issues and their scientific basis and providing guidelines for daily use in two areas: (1) selecting reference values and (2) interpretative strategies. The statement was to address the concerns of those who generate lung function reports and those who use lung function reports to assist in clinical case management. Epidemiologic and public health issues are not addressed though epidemiologic studies provide the scientific basis for many of the concepts used in interpreting lung function results. The ATS has published standardization procedures for epidemiologic studies (14). The focus of this statement is spirometry, but reference is made to other lung function tests when pertinent.

Although the statement deals primarily with adults, the conceptual issues apply to children as well. Terms and abbreviations follow the American College of Chest Physicians (ACCP)-ATS joint committee on pulmonary nomenclature recommendations (15). The next four sections deal with conceptual issues and their scientific basis; the last section deals with practical considerations and recommendations.

Sources of Variation in Lung Function Testing

Conceptual Issues Pertinent to the Interpretation of Lung Function Tests

All clinical measurements, including pulmonary function tests, are subject to (1) technical variation related to instrument, procedure, observer, subject, and their interactions; (2) biologic variation, the focus of interest of most of the nonclinical biological sciences; (3) variation caused by dysfunction or disease, the focus of clinical medicine (5). In clinical pulmonary function testing, it is important to minimize the variation caused by technical factors and to take biologic variation into account so that variations caused by disease can be properly interpreted. Sources of technical and biologic variation and the estimated magnitude of their effects are listed in tables 1 and 2.

Interpretation of pulmonary function tests depends upon establishing the variation of interest (the signal) and its relation to all other sources of variation (the noise) (5). Which sources of variation constitute signal and which noise will depend on the question being asked. For instance, in a physiologic study of the effects of posture on FEV₁, variation caused by posture would constitute the signal and all other sources of within-individual variation, the noise. Similarly, in an epidemiologic study of the effects of an occupational exposure on a work force, variation caused by exposure will constitute the signal, and all other sources of between population variation, the noise. In the clinical context, signal and noise will vary according to the clinical question. For instance, when assessing the outcome of a treatment, the signal would be the change after treatment, and the noise would be within-individual variation in the absence

TABLE 1
SOURCES OF VARIATION IN LUNG FUNCTION*

Source	Determinants
Technical	Instrument, subject, posture, observer, procedure (including number of tests), software; temperature; altitude
Biologic	
Within individual	All of the above Diurnal (circadian) and seasonal effects, endocrinologic effects
Between individual	All of the above Personal factors, including size, age, sex, physical activity, muscularity, race, and other genetic characteristics and past and present health Environmental factors, including tobacco smoke (personal and environmental), occupation, residence (urban or rural), air pollution (home, environmental), and socioeconomic status
Between population	All of the above Selection factors which determine inclusion or exclusion of certain subjects from study populations

* Based on table in reference 5 and reproduced with permission.

of treatment. When lung function tests are used as an aid in diagnosis, the signal is usually the patient's results compared with the expected result for subjects without disease but similar in the personal characteristics that determine lung function such as sex, size, age, and, possibly, race (table 1).

Technical Sources of Variation

INSTRUMENTATION

Detection of instrument problems is an integral part of interpretation. Readers should consult ATS recommendations on spirometry and DLCO, which give practical limits of acceptable instrument variability (7-9). Instruments and procedures used in developing of reference values and those used to evaluate patients should meet, and preferably exceed, current ATS recommendations.

PRECISION AND ACCURACY

In considering the variability of a test, a distinction must be made between precision and accuracy. Precision refers to the repeatability of the measurements, even if the values obtained are not accurate (16). Accuracy, which is not easy to establish, refers to how close the measurements made by an instrument are to the "true" value. Because most instruments have better precision than accuracy, between-instrument variation usually contributes more to total measurement variability than within-instrument variation.

COMPUTER SOFTWARE AND HARDWARE

Overall, the use of computers in spirometry systems has reduced technical variability; nevertheless errors associated with computers occur. Even small differences in the techniques used to calculate flow can produce relatively large differences in derived flow measurements (17, 18). It is imperative that spirometry systems using computers be validated initially and each time changes are made in software or hardware. One simple method of validating computer computations is to compare manual calculations of spirometric values with computer-calculated values. The values should be close, ± 2 to 3%, but they

will not be identical. Computers can also provide immediate feedback on the success of a subject's performance and improve overall test quality. Quality control algorithms that detect coughs, late peak flows, premature termination of effort, excessive extrapolated volumes using the back extrapolation technique, and excessive variation between maneuvers can be programmed to provide immediate feedback to the technician.

SPECIAL CONSIDERATIONS FOR TESTING CHILDREN

Equipment for testing children should have an accuracy for volume of ± 50 ml to below 0.5 L. The output for the hard copy display should be scaled to the size of the signal with a variable attenuation to a minimum of 30 mm/L. There should be a visible real-time display to encourage both the child and the technician and to ensure that effort is sustained over a sufficient time. Equipment, including mouthpieces and noseclips, should be adjustable and comfortable for children with heights as low as 120 cm. Children should be tested in a laboratory where personnel are familiar with clinical testing of children and where interpretations can be made by persons familiar with pulmonary function testing in children. Detailed recommendations for pediatric testing have recently been issued by the European Society of Clinical Respiratory Physiology (13).

Procedural Sources of Variation

The largest single source of within-subject variability is improper performance of the test. Therefore, interpretations of spirometry should include a statement about test quality before any other interpretation is rendered. The ATS (7-12), the ECCS (4), the California Thoracic Society (2), the Intermountain Thoracic Society (19), the European Society for Clinical Respiratory Physiology (13), and several texts (1, 3, 20-23) have all recognized the importance of procedure in reducing measurement variability. Readers should consult these references for detailed recommendations.

TABLE 2
ESTIMATES OF THE PROPORTION OF MEASURED BETWEEN-INDIVIDUAL VARIATION IN FEV₁ OR FVC IN ADULTS ATTRIBUTABLE TO IDENTIFIED FACTORS*

Factor	Proportion of Variation Attributable
Sex	up to 0.30
Age	0.08
Height	0.20
Weight	0.02
Ethnic differences	0.10
Technical	0.03
Unexplained†	0.27
Total	1.00

* Reproduced with permission from reference 5.

† Includes all other determinants of biologic variation discussed in SOURCES OF VARIATION IN LUNG FUNCTION TESTING whether environmental (e.g., smoking, active, and passive, occupational exposures, residential pollution, socioeconomic status) or host, (e.g., genetic, allergic, past and present respiratory health status). The latter two are usually the focus of interest to the clinical pulmonary function laboratory.

Biologic Sources of Variation

WITHIN-INDIVIDUAL (INTRAINDIVIDUAL) VARIATION

This section addresses short-term intraindividual variations in lung function that do not originate with instrumentation and are not related to disease, environment, the intake of drugs, smoking, or failure of the subject to inspire or expire maximally during spirometric maneuvers. The main residual sources of variation are: (1) body position, (2) head position, (3) effort dependence of maximal flows, and (4) circadian rhythms.

(1) *Body position.* Body position affects spirometric volumes, particularly FVC and VC, which are 7 to 8% lower in the supine than in the standing position and 1 to 2% lower in the sitting than in the standing position (24-27). Body position should be kept constant in comparison studies. The standing position may be particularly advantageous for obese subjects (28).

(2) *Head position.* Systematic increases in maximal expiratory flows have been documented during neck hyperextension (29). These increases are believed to be related to elongation and stiffening of the trachea and range from minimal to 35% of baseline values for lung volumes above FRC (60 to 80% of VC). Corresponding changes in FEV₁ have not been documented. Conversely, neck flexion may decrease peak expiratory flow rate (29) and increase airway resistance (30). Avoiding hyperextension and flexion of the neck seems sufficient to eliminate this source of variability. The effect of neck position is usually less than that of body position, but it may be important for patients tested in bed.

(3) *Effort dependency of maximal flows.* The imperative for standardization is one reason for the recommendations that the expiratory maneuver be performed with maximal effort. Nevertheless, FEV₁ may be 100 to

200 ml lower when the effort is maximal compared with submaximal efforts because the airways are narrower with respect to the exhaled volume (31-34). Variable expiratory effort may thus be a confounding factor when assessing small changes in maximal flows or timed volumes such as those resulting from bronchodilator response, therapy, or aging. When a flow-volume curve is available, peak expiratory flow may be an index of maximal expiratory effort (31). In some subjects, repeated maximal efforts may trigger bronchospasm, resulting in a progressive decrease in FVC and FEV₁ (35). This may also account for a subject's inability to achieve the reproducibility standard recommended by the ATS. It is of interest that failure to meet these reproducibility standards may itself be a measure of less than perfect health (36, 37).

(4) *Circadian rhythms.* Variations in lung function tests with a period of approximately 24 h are well documented (38-40). For maximal expiratory flows, the lowest values are usually seen in the early morning (4 to 6 A.M.), and the largest values are seen around noon (38). In healthy subjects, FEV₁ has been shown to increase by about 0.15 L in the morning and decrease by 0.05 L in the afternoon (39); for peak expiratory flow rate (PEFR), the peak-to-trough amplitude is on the order of 8% (40). Circadian variations have also been documented for airway resistance, specific airway conductance, functional residual capacity, total lung capacity, and residual volume (41-44). The mechanisms responsible for these diurnal variations in lung function have not yet been elucidated (45, 46). Much larger diurnal changes are seen in asthmatic patients who often exhibit a severe "morning dip" in pulmonary function parameters with decreases of 50% or more in PEFR (40, 41, 47, 48). As with healthy subjects, the largest values are usually seen around noon, but this pattern may be substantially shifted by the timing of treatment (49). Exaggerated circadian variations have also been observed in patients with chronic bronchitis (50, 51). Seasonal variations of respiratory function have also been recorded (49).

BETWEEN-INDIVIDUAL (INTERINDIVIDUAL) VARIABILITY: HOST FACTORS

The most important host factors responsible for interindividual variation in lung function are (1) sex and size, and (2) aging, which account for approximately 30, 22, and 8%, respectively, of the variation in adults (5) (table 2). Other sources of interindividual variation are (3) race and (4) past and present health. Approximately 27% of interindividual variation remains unexplained (5) (table 2).

(1) *Size and sex.* Size is usually measured as standing height (6, 52). Sitting height, not as easy to measure as standing height, generally explains less of the variability (53), but it may be a useful predictor in certain circumstances (e.g., when dealing with a population of mixed ethnic origins, see below). Arm span measurements provide a practical substitute for standing height in subjects unable to stand

or those with a skeletal deformity such as kyphoscoliosis (19, 54). Lung function is decreased at both extremes of weight (55, 56). Including measurements of chest circumference only slightly improves the prediction of lung function (57-60). Variations in airway and air-space dimensions and geometry also contribute to interindividual variation in lung function (61, 62). Accurate methods of measuring airway and air-space geometry are not widely available, and the contribution these measurements will make to increasing prediction accuracy is unknown. After correcting for body size, girls appear to have higher expiratory flows than do boys, whereas adult men have larger volumes and flows than do women (6, 63, 64).

(2) *Aging.* An appropriate model for lung function changes caused by aging during the adult years includes a period after adult height is attained in which there is either an increase (usual in young men) or little or no decrease in function (usual in young women), after which the function decreases at an accelerating rate with increasing age (6, 65) (see also GROWTH section below). These accelerated aging effects are typically found in longitudinal studies and not in studies based on cross-sectional data. The differences between cross-sectional and longitudinal studies are explained by both statistical issues (66-69) and cohort effects (5, 6, 52, 55, 70).

(3) *Race.* Race has been consistently shown to be an important determinant of lung function (20, 55, 58, 63, 64, 71-83). When compared with Caucasians of European descent, values for most other races usually show smaller static and dynamic lung volumes and lower forced expiratory flow rates but similar or higher FEV₁/FVC ratios. In some population groups diffusing capacity (transfer factor) is also lower (71). Regression equations derived from white populations using standing height as the measure of size usually overpredict values measured in black subjects by about 12% for TLC, FEV₁, and FVC and by approximately 7% for FRC and RV (20). People of mixed race usually have intermediate values. These differences persist after allowances are made for age, stature, smoking, air pollution, habitual activity, and altitude. The reason for the differences between the races is unclear. Differences may be due in part to differences in body build (58, 63, 64, 72-76). Blacks, on average, have a smaller trunk:leg ratio than do whites (77). The use of sitting height as an index of body size in prediction equations reduces but does not fully eliminate the observed differences between whites and blacks (58, 63, 64, 77) or the differences between Europeans, Indians, and Asians. Environmental differences, perhaps relating to nutrition, physical activity, community air pollution, and socioeconomic factors are also thought to contribute to these differences (78-85).

(4) *Past and present health.* Lung function at any one point in time reflects not only the present health of the individual but also the sum of all the insults and injuries the lung

has sustained in the past including those from the prenatal and immediate postnatal periods (86-88).

BETWEEN-INDIVIDUAL (INTERINDIVIDUAL) VARIATION: ENVIRONMENTAL FACTORS

The effects of exposure to tobacco smoke, by far the most important environmental factor known to alter lung function, are well documented elsewhere (89). In this section consideration is given to other environmental factors that account for between-individual differences in lung function.

(1) *Geographic factors.* Altitudes as high as 1,500 m do not appear to cause measurable changes in lung volumes, though measurement of some flow rates may be affected by changes in air density even at these altitudes (90-92). FEV₁ and forced expiratory flows are slightly increased at high altitudes, mainly because of the decreased density of air (93, 94). During acute exposures to altitude there may be slight reductions in VC, TLC, and FRC, most likely because of increased thoracic fluid (95). Those residing at high altitudes probably have larger lung volumes than do residents at low altitudes. The reasons are unclear because of the confounding effects of variables such as nutrition (96, 97).

(2) *Exposure to environmental and occupational pollution.* Exposure to airborne irritants such as ozone, nitrogen dioxide, sulfur dioxide, and sulfuric acid may produce measurable transient changes in pulmonary function tests in controlled human exposure experiments and epidemiologic studies (98-102). Those who are exercising and sensitive subgroups of the general population have increased responses. For example, short-term exposures (minutes) to high concentrations of SO₂ can trigger transient bronchoconstriction in exercising asthmatics (103). Reduced lung function levels and an increased rate of decline in lung function have been associated with long-term exposures to sulfur oxides, inhalable particles, and photochemical oxidants (100).

Environmental exposure to tobacco smoke appears to affect the lung function of children (104, 105) and, possibly, adults (106-108). More recent observations also show an effect on bronchial reactivity in children (109). The health effects of other indoor pollutants have not yet been conclusively established (110, 111). Exposure to occupational pollutants, including dusts, chemicals, gas, etc., may induce acute and chronic changes in lung function (112-114).

(3) *Socioeconomic status.* Adverse effects of low socioeconomic status on lung function are well documented and detectable even in industrialized countries (85, 115, 116). Low socioeconomic status is often associated with unfavorable environmental conditions such as living in polluted urban-industrial areas, increased environmental and occupational exposures, increased indoor air pollution, increased rates of respiratory illness, and decreased access to health care. Moreover, dif-

ferences in lung function attributed to genetic factors may be partly or even largely attributable to differences in socioeconomic status (84).

GROWTH

Growth affects the relationships between indices of body size and spirometric measurements in children and adolescents. Some of the determinants of lung volumes and ventilatory flows are therefore briefly reviewed here.

(1) *Relationship to height.* The relationship of ventilatory function to height from childhood through late adolescence to adulthood is not linear. Prediction equations for children are usually based on power or exponential functions of height, both of which seem to fit the data equally well (63, 64, 117-120).

(2) *Age-dependence.* Growth in standing height, measured in cross-sectional or longitudinal population studies, is not in phase with lung growth during the adolescent growth spurt (120-125). Growth in chest dimensions lags behind that of the legs (60, 122, 124, 125). In boys, standing height and VC are often not maximal by 17 yr of age (123). VC continues to increase after growth in height ceases and may not be maximal until after 25 yr of age. Girls, however, seem to attain their maximal values at about 16 yr of age (120, 122, 123). In younger subjects, FVC and FEV₁ seem to track constant percentiles over time (126). Ideally, developmental rather than chronological age should be included in prediction equations for children and adolescents, but such equations are not available or practical.

(3) *Respiratory muscles.* The opposing effects of increasing muscularity and obesity have been invoked to explain the observed increase in ventilatory function that parallels increase in body mass and the decline in lung function beyond an optimal weight (55). Likewise, an increase in lung volumes and body mass when growth in height had stopped has been attributed to an increase in muscle mass and the consequent increase in respiratory muscle force (124, 127, 128). However, data on maximal inspiratory and expiratory pressures generated at different ages are inconclusive. No differences were observed between respiratory pressures in adolescents and adults (129). In adolescents there is evidence of only a small increase in maximal respiratory pressure with growth of the lung and thorax (130-134). The average maximal respiratory pressures of boys are larger than those of girls (130-133). Although there is a large variability in maximal inspiratory and expiratory pressures between individuals of the same sex, respiratory force accounts for only a small portion of the differences in ventilatory function (134, 135).

(4) *Elastic properties.* From the neonatal period to old age, the thoracic cage grows stiffer (136). Lung recoil increases from birth to adulthood and then decreases with aging (136-143). The relatively constant FRC/TLC ratio (120) and the measurements of respiratory system mechanical properties (136) sug-

gest that changes in lung and chest recoil are well balanced during growth.

(5) *Lung volumes and ventilatory flows.* From childhood to adulthood the FEV₁/FVC ratio and the ratio of maximal expiratory flow (derived from flow-volume curves) to the FVC are almost constant. Girls generate larger expiratory flows than do boys of the same age and stature (120, 127, 135, 144, 145). This is due in part to the fact that girls have a smaller VC for the same TLC than do boys, but it may also reflect both the smaller muscle mass and the smaller number of alveoli found in girls (146). Airway tone appears to decrease in girls but not in boys after a deep inspiration (147). Finally, in children between 2 and 12 yr of age airway resistance is less in girls than in boys (148). These observations warrant using different prediction equations for boys and girls at all ages.

Statistical Considerations in the Derivation of Prediction Equations

General Comments

Reference equations provide a context for evaluating the pulmonary function values of an individual patient or subject in comparison to the distribution of measurements in a reference population. The clinician's request for tests often contains the implicit question: Are these results below the "lower limit of normal?" This section deals with statistical aspects and limitations of this concept.

Characterizing the Distribution and Determinants of Lung Function in Reference Populations

Subjects with similar characteristics for the variables that affect lung function (sex, age, height, race) can be grouped together in a stratum or a cell. Comparing the performance of an individual subject with the values generated from a reference population requires one to know something about the data in the appropriate cell, specifically: (1) the number in the cell, (2) measures of central tendency such as the mean value, (3) estimates of dispersion such as variance or standard deviation (SD), and (4) information about the symmetry of the distribution. If the number of subjects in each cell is sufficient, lung function can be described by providing descriptors of the distribution such as mean and SD. Such tabulations are infrequently used for lung function because there are too many possible cells (consider all possible combinations of age and height). Regression equations are an economical and efficient alternative method to describe expected values as a function of sex, height, and age. Regression techniques assume that pulmonary function varies in a symmetric fashion about the mean value in each cell and that the variance about the mean is constant from one cell to another. The closer the distribution of pulmonary function values comes to symmetry or, better still, to a Gaussian distribution within cells, the more it is

possible to take advantage of the simplifications possible with Gaussian data.

Evaluating Prediction Equations

Linear regression is the most common but not the only model used to describe pulmonary function data in adults. Such equations perform less well at the edges of the data distribution and in those cells where there are few data. Estimates are likely to be misleading if they go beyond the range of the independent variables used to create the equation. Regression analyses are often simplified by restricting the range of possible values to cells (ranges of height and age) in which reasonable predictions are possible. One approach to regression analysis is to use separate simple regression equations for several different age groups (149, 150). This approach may introduce conflicting estimates at the points of transition between equations.

Complex equations may provide more biologically plausible models and reduce the average differences between observed and predicted values for every cell (e.g., age and height) in comparison with simple linear equations. The improved predictions, however, usually come at the cost of increased complexity of computation.

The most commonly reported measures of how well regression equations fit the data they describe are the square of the correlation coefficient (r^2) and the standard error of the estimate (SEE). The proportion of variation in the observed data explained by the independent variables is measured by r^2 . The SEE is the average SD of the data around the regression line. SEE will decrease and r^2 will increase as regression methods diminish the differences between predicted and observed pulmonary function values in the reference population. When the same equations are used to describe a different population, SEE will invariably be larger, and r^2 will be smaller. In addition, since these statistics reflect average characteristics of the regression, r^2 and SEE may not reflect the ability of the equation to describe the tails of the distribution or the limits of "normal," and therefore are not sufficient criteria on which to choose the best equations to evaluate a clinical population.

Distributions and "Lower Limits of Normal"

Distributions of FEV₁ and FVC in population studies are usually found to be close to Gaussian in the middle age range, but not at the extremes. Distributions of flow measurements and ratio measures (e.g., FEV₁/FVC) are usually not symmetric (149). Transformation or age stratification of the data may help produce symmetric distributions about the mean. Ideally, publications describing reference populations should include not only the prediction equations but also a means of defining their lower limits. In the absence of explicit recommendations, a lower limit can be estimated from a regression model. For spirometry, values below the fifth percentile are taken as below the expected range (below

the "lower limit of normal"), and those above the fifth percentile are taken as within the expected range (149, 150). Percentiles can be calculated directly from the data if there are sufficient measurements within each category (56, 149, 150). If individual observations have a distribution close to Gaussian, the value of the fifth percentile can be roughly estimated as: Lower limit of normal = Predicted value $-1.645 \times \text{SEE}$. Ideally, the SD of the residuals should be constant for all cells. This is true for some equations for adults (149). In other studies, the estimated SD for the logarithm of FVC and FEV₁ among preadolescent children, and for height-adjusted FVC and FEV₁ among adults, appears to be constant for each sex and race (56). If SD is proportional to the predicted mean value, as it may sometimes be in children (126), the fifth percentile can be estimated as a constant proportion of the predicted mean, i.e., a percent of predicted. A comparison of several prediction equations for spirometry has shown substantial agreement using the fifth percentile criterion but not using the $-1.645 \times \text{SEE}$ criterion (151).

Sources, Uses, and Selection of Reference Values

General Comments

Normal ventilatory function has come to mean the average spirometric values of a representative sample of healthy subjects drawn from the general population. Various criteria for excluding study subjects have been suggested based on (1) past and present medical history (e.g., presence of respiratory symptoms such as cough, sputum production, and wheezing; presence of physician-diagnosed respiratory disease such as asthma, bronchitis, emphysema, or tuberculosis; hospitalization for lung or chest conditions; the presence of heart disease; employment exposures; and cigarette smoking); (2) physical examination; and (3) chest radiographic findings. The most important selection criteria are those based on a history of past disease and respiratory symptoms. A reference population should, ideally, be representative of the general population from which the clientele of the laboratory comes. Although a random sample of a population is ideal, one report found that once hospital patients were excluded, the method for selecting the study sample used to generate reference values had relatively little effect on either the mean value or the range of values obtained (152).

Sources of Reference Equations

In the 1960s, a number of reference equations were published based on data gathered in specific population groups such as laboratory personnel, workers in a particular industry, school populations, subjects attending a specific clinic, volunteers, and general industrial workers (153-157). Some are derived from population-based data gathered in epidemiologic studies carried out for other purposes; in these studies reference equations are a

byproduct (56, 63, 126, 149, 150). Others are based on data gathered specifically for the creation of reference equations (91, 158).

Determination of the "Normal Range"

FIXED PERCENT OF PREDICTED VALUES

The practice in many clinical laboratories has been to classify values of FVC and FEV₁ less than 80% of predicted as abnormal. This fixed value has no statistical basis in adults (91, 159-162). Although some studies have shown that for adults of average age and height, 80% of predicted FVC and FEV₁ is close to the fifth percentile, use of a fixed value will result in shorter, older subjects being more readily classified as "abnormal" (159, 162), whereas taller, younger adult subjects are more likely to be erroneously classified as "normal." The practice of using 80% of predicted as the lower limit of normal for FEF₂₅₋₇₅, or the instantaneous flows will also cause important errors since, for these flows, the lower limits of normal are closer to 50% of predicted (149, 150). The practice of using a fixed percent of predicted as a lower limit of normal may be acceptable in children (163) (see section on DISTRIBUTIONS AND LOWER LIMITS OF NORMAL).

FEV₁/FVC RATIO

Defining a fixed FEV₁/FVC ratio as a lower limit of normal is not recommended in adults because FEV₁/FVC is inversely related to age and height (91, 149, 150). The use of a fixed ratio will therefore result in an apparent increase in the prevalence of impairment associated with aging or with age-confounded factors such as cigarette smoking or occupational exposures. In addition, some athletes have values for FVC that are relatively larger than those for FEV₁, resulting in a lower FEV₁/FVC. This may also be true of workers in some physically demanding occupations such as mining and deep-sea diving.

PERCENTILES AS THE "LOWER LIMIT OF NORMAL"

One statistically acceptable approach for establishing lower limits for any spirometric measure is to define the lowest 5% of the reference population as below the lower limit of normal (see section on DISTRIBUTIONS AND LOWER LIMITS OF NORMAL). This implies a 5% false positive misclassification, a rate generally considered acceptable.

Smoking as an Independent Variable

Subjects who smoke cigarettes usually have lower values for spirometry and forced expiratory flows even if they meet the same health criteria for "normal" as nonsmokers (164). Smoking has both biologic and technical effects on DLCO (9, 165). A clear choice for the most appropriate method of adjusting spirometric indices for the effect of smoking is not readily evident from published data in which any of the following have been used: smoking status (current smoker or exsmoker), amount currently smoked, duration of smok-

ing, and pack-years of smoking. Neglecting the correlation of some of these factors (e.g., pack-years) with age can introduce errors in analyzing the effect of smoking. In one study, the lifetime loss of FEV₁ for the average male smoker was 7.4 ml/pack-year, and for the average female smoker it was 4.4 ml/pack-year (164). Current smoking also adds an acute deficit in FEV₁ of approximately 150 ml over and above the cumulative effect of lifetime smoking (164, 166).

The distribution of a smoking variable in the reference population and its relation to other health indicators will affect the regression term calculated for smoking. For example, in one study a twofold greater deficit in spirometric measurements in relation to pack-years was found in subjects with chronic cough compared with those without chronic cough (167). The mean spirometric value may not be the best index for determining lung function deficit caused by smoking since the effect on the susceptible minority tends to be overwhelmed by the unaffected majority (168). Whether the effects of smoking are similar across other independent variables such as sex and age is unknown. Some of the sex differences in smoking-associated pulmonary dysfunction may be related to differences in smoking behavior (169). The effect of smoking also increases with age (166). The effect of smoking on the developing lung is likely to be different from the effect of smoking on the adult lung.

Finally, the effects of smoking cessation on pulmonary function are inconsistent. Exsmokers are found to have both reversible and irreversible ventilatory decrements (164, 166, 170). Most cross-sectional studies in older subjects have found older exsmokers to have values intermediate between those who continue to smoke and those who have never smoked. Young exsmokers may exhibit higher spirometric values than never smokers, probably as a result of health selection effect (134, 171). Whether the pulmonary function of ex-smokers is better or worse than that of current smokers probably depends on the age of the subjects, how long they have smoked, and on why they abandoned smoking.

Cross-sectional and Longitudinal Predictions

Cross-sectional data are subject to a bias called "cohort" effect. A person who is 40 yr of age today is different from one who became 40 two decades ago because of a variety of host and environmental factors (6, 52). The age-related lung function deficit predicted from cross-sectional data tends to be greater than that predicted from longitudinal pulmonary function data in adults (67-70) and children (172-174). Prediction equations based on cross-sectional data are appropriate for determining the prevalence of pulmonary function impairment in defined populations. They are less well-suited to determine age-related events including the incidence or progression of impairment. Percentiles of ad-

justed lung function (similar to those used by pediatricians to assess growth) have been advocated by several investigators for assessment of both growth and decline of pulmonary function (56, 63, 126). A person would be expected to track along the same percentile as he or she ages if the loss (gain) in function was at a rate comparable to that of the reference population.

Criteria for Selection of Reference Values

Criteria for selecting reference values to be used in the clinical or in the epidemiologic context fall into three categories: methodologic, epidemiologic, and statistical (5).

(1) *Methodologic criteria.* If possible, reference values should be based on data obtained by trained operators using equipment and techniques that meet ATS criteria (7-12). In contrast with the use of the FVC in America, predictions of VC from Europe are usually based on inspiratory vital capacity (IVC) or slow expiratory vital capacity (EVC). The IVC and EVC are, on average, somewhat larger than FVC in healthy subjects; in subjects with airflow limitation, the differences are more pronounced (4, 175).

(2) *Epidemiologic criteria.* The population from which the subjects are drawn should be similar with respect to age, height, sex, and ethnic composition to the population to whom the prediction values are to be applied. Prediction equations should use age, height, sex, and, probably, ethnic group as independent variables. For most clinical uses they should be based on cross-sectional studies of lifetime nonsmokers.

(3) *Statistical criteria.* These are discussed in STATISTICAL CONSIDERATIONS IN THE DERIVATION OF PREDICTION EQUATIONS. Both biologic plausibility and simplicity in the model used to develop prediction equations are im-

portant issues in the selection of reference values. However, neither is as important as the choice of a reference population that (1) provides an appropriate comparison for the subjects to be evaluated, and (2) is based on measurements made with instruments and methods comparable to those used in the laboratory for which reference values are being selected (2, 5).

Published Reference Equations

For the convenience of readers, selected published reference equations for adult whites and blacks and scaling factors for blacks currently in use are listed in tables 3 to 9. A comprehensive listing up to 1983 was published by the ECCS (4). The results of a survey of reference equations used in North American pulmonary teaching centers is shown in table 10. Equations for children and adolescents are detailed elsewhere (13, 63, 117-119, 131, 149, 176, 177). Laboratories should use the published reference equations that most closely describe the populations tested in their laboratories. This may also be assessed empirically by comparing the results for a group of 20 to 40 local reference subjects with those provided by the intended reference equations. The local reference subjects should be appropriately selected by age, ethnic group, and sex, to match the clientele of the laboratory and should meet the selection criteria listed in section CRITERIA FOR SELECTION OF REFERENCE VALUES.

Limitations of Currently Available Equations

Reference equations now available include relatively few results for adolescents and the elderly. Even fewer equations span the ages from grade school through adulthood and, with few exceptions, they are discontinuous for children and adults (55, 178). Older sub-

jects reflect their lifetime experiences with respect to nutrition, health status, and other factors and are therefore subject to a cohort effect. Most equations in current use are based on linear statistical models. All these aspects are subject to change. For this reason, reference equations should be reviewed regularly.

Interpretative Strategies

Conceptual Issues Concerning Normality and the Limits of Normal

The word "normal" is used in a number of ways (5, 6, 13, 179). In popular use it means ideal, conventional, or usual. It is used by statisticians to describe a specific distribution about a central tendency and by biologists in ways that vary according to their focus of interest. Anatomists, for instance, use it to describe structural variations consistent with good function; physiologists use it to describe variations that preserve the "internal milieu," and clinicians use it to describe variation within the limits of "good health" and exclusive of "disease" (5). Issues of biologic "normality" are discussed in greater detail elsewhere, and interested readers are referred to those reviews (5, 6, 179-181).

Because most laboratory tests are quantitative variables with overlap between measurements in healthy and diseased subjects, the idea of a range of values defining biologically "normal" is, in the view of its critics, misleading (5, 6, 182). For instance, in interpreting laboratory test results where there is an overlap between healthy and diseased populations, the "normal" range should theoretically change with different disease processes and with the clinical questions being asked (181). It has also been pointed out that selecting a normal range "requires careful evaluation of benefit in terms of morbidity or mortality, inconvenience, and distress caused to

TABLE 3
PREDICTED VALUES FOR FEV₁ AND FVC DERIVED FROM SELECTED STUDIES OF NONSMOKING CAUCASIAN MEN*

First Author, Year (Ref)	Age Range (yr)	Number Studied	FEV ₁ † for Ht 1.75 m, Age 45 yr	Regression Coefficient		RSD or SEE	FVC† for Ht 1.75 m, Age 45 yr	Regression Coefficient		RSD or SEE
				Ht	Age			Ht	Age	
Morris, 1971 (224)	20-84	517	3.63	3.62	-0.032	0.55	4.84	5.83	-0.025	0.74
Cherniack, 1972 (225)	15-79	870	3.74	3.59	-0.023	NR	4.52	4.76	-0.014	NR
Quanjer, 1977 (4)	21-64	189	3.59	4.05	-0.031	0.43	4.51	6.11	-0.032	0.56
Crapo, 1981 (91)	15-91	125	3.96‡	4.14	-0.024	0.49	4.89‡	6.00	-0.021	0.64
Knudson, 1983 (149)	25-84	86	3.81	6.65	-0.029	0.52	4.64	8.44	-0.030	0.64
Dockery, 1985 (56)	25-74	624	3.78	Equation nonlinear§		0.40	4.72	Equation nonlinear§		0.47
Roca, 1986 (226)	20-70	443	3.95	4.99	-0.021	0.44	5.15	6.78	-0.015	0.53
Paoletti, 1986 (150)	29-64	59	3.83	4.94	-0.027	0.48	5.06	7.24	-0.027	0.58
Miller, 1986 (158)	18-85	176	3.94	5.66	-0.023	0.41	4.84	7.74	-0.021	0.51

Definition of abbreviations: RSD = residual standard deviation; SEE = standard error of the estimate; NR = not reported.

* To be included studies had to (1) include men and women; (2) adequately describe the methods used; (3) analyze spirometric values in terms of age and height. Instruments of measurement were: water spirometer (56, 91, 224); dry or wedge spirometer (158, 225); pneumotachograph (4, 149, 150, 226). Equation to predict FEV₁ or FVC using this table:

$$\text{Predicted FEV}_1 \text{ or FVC} = \text{Predicted value}^\dagger \text{ for Ht } 1.75 \text{ m, Age } 45 + \text{Ht Coefficient} \times (\text{Ht} - 1.75) + \text{Age Coefficient} \times (\text{Age} - 45)$$

† Predicted value for Ht = 1.75 m, Age = 45.

‡ Studies carried out at an altitude of 1,400 m.

§ FEV₁ = Ht² (1.541 - 4.06 × 10⁻³ Age - 6.14 × 10⁻³ Age²); FVC = Ht² (1.75 - 1.35 × 10⁻⁴ Age - 1.01 × 10⁻⁴ Age²).

TABLE 4
PREDICTED VALUES FOR FEV₁ AND FVC DERIVED FROM SELECTED STUDIES OF
NONSMOKING CAUCASIAN WOMEN*

First Author, Year (Ref)	Age Range (yr)	Number Studied	FEV ₁ † for Ht 1.65 m, Age 45 yr	Regression Coefficient		RSD or SEE	FVC† for Ht 1.65 m, Age 45 yr	Regression Coefficient		RSD or SEE
				Ht	Age			Ht	Age	
Morris, 1971 (224)	20-84	471	2.72	3.50	-0.025	0.47	3.54	4.53	-0.024	0.52
Cherniack, 1972 (225)	15-79	452	2.87	2.37	-0.019	NR	3.36	3.08	-0.015	NR
Quanjer, 1977 (4)	21-64	514	2.71	3.17	-0.031	0.35	3.39	4.64	-0.027	0.42
Crapo, 1981 (91)	15-84	126	2.92‡	3.42	-0.026	0.33	3.54‡	4.91	-0.022	0.39
Knudson, 1983 (149)	20-87	204	2.79	3.09	-0.020	0.39	3.36	4.27	-0.017	0.49
Dockery, 1985 (56)	25-74	1,830	2.79	Equation nonlinear§		0.40	3.41	Equation nonlinear§		0.47
Roca, 1986 (226)	20-70	427	2.87	3.17	-0.025	0.31	3.72	4.54	-0.021	0.40
Paoletti, 1986 (150)	21-64	313	2.84	2.43	-0.020	0.29	3.78	4.12	-0.015	0.39
Miller, 1986 (158)	18-82	193	2.91	2.68	-0.025	0.33	3.59	4.14	-0.023	0.45

* To be included studies had to (1) include men and women; (2) adequately describe the methods used; (3) analyze spirometric values in terms of age and height. Instruments of measurement were: water spirometer (56, 91, 224); dry or wedge spirometer (158, 225); pneumotachograph (4, 149, 150, 226). Equation to predict FEV₁ or FVC using this table:

$$\text{Predicted FEV}_1 \text{ or FVC} = \text{Predicted value}^\dagger \text{ for Ht 1.65 m, Age 45} + \text{Ht Coefficient} \times (\text{Ht} - 1.65) + \text{Age Coefficient} \times (\text{Age} - 45)$$

† Predicted value for Ht = 1.65 m, Age = 45 yr.

‡ Studies carried out at an altitude of 1,400 m.

§ FEV₁ = Ht² (1.332 - 4.06 × 10⁻³ Age - 6.14 × 10⁻⁵ Age²); FVC = Ht² (1.463 - 1.35 × 10⁻⁴ Age - 1.01 × 10⁻⁶ Age²).

TABLE 5
PREDICTED VALUES FOR FEV₁ AND FVC DERIVED FROM SELECTED STUDIES OF
BLACK MEN AND WOMEN*

First Author, Year (Ref)	Age Mean or Range	Number Studied	FEV ₁ for Ht and Age†	Regression Coefficients		RSD or SEE	FVC for Ht and Age†	Regression Coefficients		RSD or SEE
				Ht	Age			Ht	Age	
Men										
			Ht 1.75 m Age 45 yr				Ht 1.75 m Age 45 yr			
Johannsen, 1968 (227)	20-50	120	2.96‡	2.87	-0.017	0.46	4.07‡	4.09	-	0.52
Miller, 1970 (228)	35-54	96	3.05	3.40	-0.024	0.37	3.79	4.44	-0.024	0.46
Oscherwitz, 1972 (81)	50.3 ± 6.6	110	2.94	2.99	-0.031	0.64	3.78	3.70	-0.027	0.68
Rossiter, 1974 (229)	21-70	147	3.04	4.51	-0.027	0.52§	3.84	5.77	-0.019	0.59§
Lapp, 1974 (230)	34.9 ± 11.9	79	3.53	3.54	-0.025	0.23	4.11	3.94	-0.021	0.32
Cookson, 1976 (231)	43.6 ± 15.1	141	3.12	2.20	-0.024	0.50	3.74	3.90	-0.017	0.65
Patrick, 1976 (232)	18-65	213	3.11	4.23	-0.023	NR	3.72	3.51	-0.025	NR
Women										
			Ht 1.65 m Age 45 yr				Ht 1.65 m Age 45 yr			
Johannsen, 1968 (227)	20-50	100	2.25‡	2.18	-0.013	0.34	2.74‡	2.51	-0.015	0.35
Miller, 1970 (228)	35-54	109	2.19	2.45	-0.018	0.31	2.74	3.15	-0.020	0.38
Cookson, 1976 (231)	36.7 ± 11.6	102	2.35	2.40	-0.028	0.41	2.86	3.00	-0.019	0.42
Patrick, 1976 (232)	18-65	117	2.10	1.49	-0.014	NR	2.64	3.17	-0.020	NR

* Instruments of measurement used were: water spirometer (227, 229, 231), a dry or bellows spirometer (228, 230), and various others (81, 232). Predicted values for men and woman are calculated as shown in footnotes to tables 3 and 4.

† Predicted value for a 45-yr-old man 1.75 m tall, and a 45-yr-old woman 1.65 m tall.

‡ Corrected from ATPS to BTPS conditions, assuming a spirometer temperature of 22° C.

§ Includes caucasian subjects.

subjects by further investigation and treatment, and the costs of making the wrong decision" (182). The "normal" range only gives information about the distribution of test results in the healthy population from which they were derived. It says nothing about the true positive rate, the false negative rate, or the predictive power of a positive test.

To draw inferences about the presence of disease from a test, one should, ideally, know the prior probability that the patient has the disease and the distributions of test values for subjects with and without the disease in question. Although this ideal is rarely met,

clinicians must use their understanding of the clinical situation to put an interpretation in proper perspective.

Obstructive and Restrictive Ventilatory Defects

DEFINITION OF AN OBSTRUCTIVE DEFECT

An obstructive ventilatory defect may be defined as a disproportionate reduction of maximal airflow from the lung with respect to the maximal volume (VC) that can be displaced from the lung. It indicates airflow limitation and implies airway narrowing during expiration. The earliest change associated with flow

limitation in small airways is thought to be slowing in the terminal portion of the spirogram even when the initial part of the spirogram is unaffected (1, 21-23). This slowing is reflected in a proportionally greater reduction in the instantaneous flow measured after 75% of the FVC has been exhaled (FEF₇₅) or in FEF_{25-75%} than in FEV₁. Abnormalities in these midrange flow measurements during a forced exhalation are, however, not specific for small airway disease and, though suggestive, should not be used to diagnose small airway disease in individual patients (183). As airway disease becomes more advanced and/

TABLE 6
PREDICTED VALUES FOR FEV₁/FVC% DERIVED FROM SELECTED STUDIES OF CAUCASIAN AND BLACK MEN AND WOMEN*

First Author, Year (Ref)	Age Range (yr)	Number Studied	FEV ₁ /FVC%† for		Regression Coefficients		RSD or SEE	Number Studied	FEV ₁ /FVC%† for		Regression Coefficients		RSD or SEE
			Ht 1.75 m and Age 45 yr	Ht	Ht	Age			Ht 1.65 m and Age 45 yr	Ht	Age		
Caucasian Men													
Quanjer, 1977 (4)	21-64	189	78.4	—	-0.16	5.3	514	80.2	—	-0.24	6.4		
Crapo, 1981 (91)	15-91	125	80.9‡	-13.0	-0.15	4.8	126	81.9‡	-20.2	-0.25	5.3		
Knudson, 1983 (149)	25-85	86	82.0	—	-0.11	6.3	204	82.6	-18.5	-0.19	7.6		
Paoletti, 1986 (150)	8-64	263	75.9	-5.3	-0.23	6.1	538	70.5	-4.3‡	-0.31	5.8		
Miller, 1986 (158)	18-85	176	80.5	-13.1	-0.15	5.6	193	82.3	-21.5	-0.15	6.8		
Black Men													
Johannsen, 1968 (227)	20-50	120	75.0	—	-0.29	8.6							
Oscherwitz, 1972 (81)	50.3 (± 6.6)	110	77.7	4.2	-0.32	10.2							
Rossiter, 1974 (229)	21-70	147	77.2	0.62	-0.34	7.2§							
Cookson, 1976 (231)	43.6 (± 15.1)	141	81.4	—	-0.25	10.7	102	82.3	—	-0.38	11.7		
Black Women													

* Table comprises studies cited in tables 3 to 5, which also reported values for FEV₁/FVC% analyzed in relation to height and age. For the instruments of measurement used, see footnotes to tables 3 to 5. Note: studies of Caucasian subjects were confined to nonsmokers; studies of black subjects included all smoking categories. Predicted values for FEV₁/FVC are calculated as shown in footnotes to tables 3 and 4. Only one study gives equations for black women.

† Predicted value for a 45-yr-old man 1.75 m tall, and a 45-yr-old woman 1.65 m tall.

‡ Studies carried out at an altitude of 1,400 m.

§ Includes Caucasian subjects.

‡ Coefficient not significant.

TABLE 7
PREDICTED VALUES FOR DIFFUSING CAPACITY (DL_{CO}) AND K_{CO} (DL_{CO}/VA) DERIVED FROM SELECTED STUDIES OF MEN AND WOMEN*

First Author, Year (Ref)	Age Mean ± SD or Range	Number Studied	DL _{CO} † for		Regression Coefficients		RSD or SEE	DL _{CO} /VA† for		Regression Coefficients		RSD or SEE
			Ht and Age	Ht	Ht	Age		Ht	Age			
Men												
			Ht 1.75 m, Age 45 yr					Ht 1.75 m, Age 45 yr				
Billiet, 1963 (233)	20-75	57	35.3	57.6	-0.24	4.2	4.96	—	-0.04	0.92		
Cotes, 1965 (20)	19-72	127	30.3	32.5	-0.20	5.1	4.83	—	-0.04	0.81		
Tecuiescu, 1970 (234)	19-67	47	32.6	33.3	-0.30	4.2	5.17‡	—	-0.04	0.73		
Van Ganse, 1972 (235)	25-79	70	29.3	16.4	-0.20	3.8	5.60	-0.90	-0.03	1.07		
Frans, 1975 (236)	39 ± 12	64	33.3	28.5	-0.14	4.2	NR					
Marcq, 1976 (237)	17-79	64	29.9	10.4	-0.20	3.9	4.59	—	-0.03	0.65		
Salorinne, 1976 (238)	20-69	69	30.7	14.2	-0.23	3.6	5.02	-3.53	-0.03	0.63		
Crapo, 1981 (239)	15-91	123	36.6§	41.6	-0.22	4.8	5.45§	—	-0.03	0.84		
Miller, 1983 (165)	43 ± 16	74	31.4	16.4	-0.23	4.8	4.77	-2.24	-0.03	0.73		
Paoletti, 1985 (240)	19-64	80	37.1	44.1	-0.19	5.8	4.81	-0.12††	-0.02	0.71		
Knudson, 1987 (241)	25-84	71	38.4	35.5	-0.27	4.6	5.61	-2.35††	-0.04	0.80		
Roca, 1990 (242)	20-70	194	33.6	36.7	-0.20	4.4		Equation nonstandard†				
Women												
			Ht 1.65 m, Age 45 yr					Ht 1.65 m, Age 45 yr				
Billiet, 1963 (233)	20-68	41	25.2	21.9	-0.16	3.6	5.55	—	-0.03	0.85		
Van Ganse, 1972 (235)	24-76	72	20.3	16.8	-0.16	3.6	5.61	-0.17	-0.01	0.99		
Salorinne, 1976 (238)	20-69	101	25.0	21.9	-0.12	2.8	5.27	-3.96	-0.01	0.74		
Hall, 1979 (243)	27-74	113	30.1**	28.3	-0.19	4.1	5.66**	—	-0.02	0.74		
Crapo, 1981 (239)	17-84	122	27.4§	25.6	-0.14	3.6	5.46§	—	-0.03	0.78		
Miller, 1983 (165)	43 ± 15	130	23.7	16.0	-0.11	4.0	4.62	-1.81	-0.02	0.80		
Paoletti, 1985 (240)	18-64	291	27.9	15.7	-0.07	4.3	4.85	-2.51	-0.02	0.85		
Knudson, 1987 (241)	20-86	99	28.2	18.7	-0.15	4.5	5.37	-2.78††	-0.03	0.85		

* Table refers to DL_{CO} and includes predicted values from published reports in which the number of subjects studied and their age were given and in which equations for DL_{CO} were described in terms of height and age according to ATS recommendations (9). All but one study (20) refer to nonsmokers. Residual volume or FRC was measured as follows: single-breath helium dilution (165, 234, 236-242), multiple-breath helium dilution (20, 233, 243), open circuit N₂ washout (235). Predicted values for DL_{CO} and DLVA are calculated as shown in footnotes to tables 3 and 4.

† Predicted value for a 45-yr-old man 1.75 m tall, and a 45-yr-old woman 1.65 m tall.

‡ Results adjusted to 1 STPS.

§ Measurements made at an altitude of 1,400 m.

|| Correction for breathholding time as in the Epidemiology Standardization Project (240, 241). Note that calculated DL is sensitive to the methods used to calculate breathhold time.

† Form of the equation not that recommended by the ATS.

** Results calculated for all smoking categories and adjusted for smoking effect.

†† Coefficient not significant.

TABLE 8
PREDICTED VALUES FOR TOTAL LUNG CAPACITY (TLC) AND RESIDUAL VOLUME (RV)
DERIVED FROM SELECTED STUDIES OF MEN AND WOMEN*

First Author, Year (Ref)	Age Mean or Range	Number Studied	TLC† for Ht and Age	Regression Coefficients		RSD or SEE	RV† for Ht and Age	Regression Coefficients		RSD or SEE
				Ht	Age			Ht	Age	
Men										
			Ht 1.75 m, Age 45 yr				Ht 1.75 m, Age 45 yr			
Goldman, 1959 (92)	44 ± 17	44	6.61	9.40	-0.015	0.65	2.04	2.70	0.017	0.39
Cotes, 1965 (20)	19-72	127	6.68	8.67	-	0.91		Not reported		
Boren, 1966 (155)	20-62	422	6.35	7.80	-	0.87	1.62	1.90	0.012	0.53
Black, 1974 (244)	16-59	83	6.84	7.80	-	0.68	2.15	3.80	0.034	0.57
Crapo, 1982 (245)	15-91	123	6.72	7.95	0.003	0.79	1.87	2.16	0.021	0.37
Women										
			Ht 1.65 m, Age 45 yr				Ht 1.65 m, Age 45 yr			
Goldman, 1959 (92)	38 ± 16	50	5.18	7.90	-0.008	0.53	1.78	3.20	0.009	0.37
Grimby, 1963 (246)	18-72	58	5.05	7.31	-0.016	0.52	1.44	2.92	0.008	0.35
Black, 1974 (244)	16-59	110	5.20	6.40	-	0.62	1.76	2.30	0.021	0.46
Hall, 1979 (243)	27-74	113	5.30	7.46	-0.013	0.51	1.80	2.80	0.016	0.31
Crapo, 1982 (245)	17-84	122	5.20	5.90	-	0.54	1.73	1.97	0.020	0.38

* Only one (245) of these studies conforms strictly to the ATS recommendations for spirometry (8); references 20, 155, 243, 244 included all smoking categories, and in two (92, 246) smoking status was not defined. Residual volume was measured as follows: helium rebreathing (20, 92, 243, 246), whole-body plethysmograph (244), single-breath helium dilution (245), and helium rebreathing on open circuit N₂ washout in one study (155). Predicted values for TLC and RV are calculated as shown in footnotes to tables 3 and 4.
† Predicted value for a 45-yr-old man 1.75 m tall, and a 45-yr-old woman 1.65 m tall.

or more proximal airways become involved, timed segments of the spirogram such as the FEV₁ will become reduced out of proportion to the reduction in VC.

DEFINITION OF A RESTRICTIVE DEFECT

A restrictive ventilatory defect is characterized physiologically by a reduction in TLC. One may infer the presence of a restrictive ventilatory defect when VC is reduced and FEV₁/FVC is normal or increased. Severe airflow limitation is another common cause of a reduced VC either because airflow is so slow the subject cannot continue to exhale long enough to complete emptying or because airways collapse. Occasionally, patients will have a small VC, a normal FEV₁/FVC, and a normal TLC. If there is a contradiction between VC and TLC in defining restriction the classification should be based on TLC.

Bronchodilator Response

Bronchial responsiveness is an integrated physiologic mechanism involving airway epithelium, nerves, mediators, and bronchial smooth muscle. Because the within-individual difference in response to a series of different bronchodilators is variable, and as many as 20 to 30% of responsive subjects will respond to one type of agent but not to another (184), the assumption that a single test of bronchodilator response is adequate to assess both the underlying airway responsiveness and the potential for therapeutic benefits of bronchodilator therapy is overly simplistic (185). The correlation between bronchoconstriction and bronchodilator responses is imperfect, and it is not possible to infer with certainty the presence of one from the other.

Data on the percent change in FVC, FEV₁, and FEF_{25-75%}, after bronchodilator administration in general population studies as well as in patient populations are summarized in

table 11. These studies showed a tendency for the calculated bronchodilator response to increase with decreasing baseline VC or FEV₁, whether response was considered as an absolute change or as a percent of the initial value. Bronchodilator responses in patient-based studies are, not surprisingly, somewhat higher than those in general population studies (table 11).

Interpretation of change after a bronchodilator should be made in light of the clinical question. If the question is whether a patient has an increased bronchodilator response, the appropriate reference is probably one of the population-based studies. If the question is whether the patient is different from other patients or from previous visits, patient groups may provide the most appropriate reference data.

There is no clear consensus on what constitutes reversibility in subjects with airflow obstruction (192). In part, this is because there

TABLE 9
FACTORS FOR ADJUSTING REFERENCE
VALUES FOR CAUCASIANS WITH A
VIEW TO THEIR BEING USED
FOR BLACK AMERICANS*

FEV ₁	0.88†
FVC	0.88†
FEV ₁ /FVC	0
TLC	0.88
RV	0.93‡
RV/TLC	1.05
Diffusing Capacity (transfer factor)	0.93
Ti/VA (BTPS)	1.05

* Source: Rossiter and Weill with annotation (229). Although the average Caucasian admixture in studies of Black Americans varies, a reasonable average is 22% (247).

† Also apply to women younger than 55 yr of age; in older subjects, the correction may be larger (approximately 0.80; Dockery et al. [56]).

‡ A larger correction (approximately 0.88) was proposed by Lapp et al. (230).

TABLE 10
SURVEY OF SPIROMETRY REFERENCE EQUATIONS USED IN
NORTH AMERICAN PULMONARY TRAINING CENTERS*

	FVC or VC		FEV ₁		FEV ₁ /FVC†	
	M	F	M	F	M	F
Morris et al. (224)	65	65	65	65	58	60
Crapo et al. (91)	27	27	27	27	29	29
Knudson et al. (149)	24	24	25	25		
Kory et al. (153)	7		8			
Kory et al. (249)		7		8		
Cherniack et al. (225)	3	3	4	4		
Miller et al. (180)	2	2	2	2	2	2
Other studies‡	11	11	8	8	11	9

* Based on a questionnaire survey of adult respiratory disease training programs in the United States and Canada. Responses from 139 of 180 institutions are summarized (248).

† Thirty-nine centers predicted FEV₁/FVC by dividing predicted FEV₁ by predicted FVC.

‡ Studies cited only once.

TABLE 11
RESPONSE TO BRONCHODILATOR: RESULTS FROM SELECTED POPULATION STUDIES

Population	Agent/Mode of Delivery	FVC	FEV ₁	FEF _{25-75%} or FEF ₅₀	Comments
1,063 subjects 8-75 yr of age General population sample from Tucson, AZ (186)	Two inhalations of isoproterenol via metered-dose inhaler	10.7% (403 ml)	7.7% (315 ml)	20%	95th percentile for percentage change from baseline (absolute value in parentheses)
2,609 subjects; random sample of three areas in Alberta, Canada (187)	500 µg terbutaline administered via spacer	—	Females 9% (224 ml) Males 9% (338 ml)	—	95th percentile for percentage change from baseline in asymptomatic never smokers with FEV ₁ > 80% predicted (absolute value in parentheses)
75 selected normal subjects (188)	Two inhalations from a Bronkometer™ metered-dose inhaler	5.1% (231 ml)	10.1% (365 ml)	48.3%	Upper 95% confidence limits (two-tailed) for percentage change from baseline

RESPONSE TO BRONCHODILATOR: RESULTS FROM SELECTED PATIENT STUDIES					
Population	Agent/Mode of Delivery	FVC	FEV ₁	FEF _{25-75%} or FEF ₅₀	Comments
40 patients referred to pulmonary function lab (189)	Placebo	14.9% (340 ml)	12.3% (178 ml)	45.1%	Upper 95% confidence interval change after placebo inhalation. Absolute values in parentheses.
985 patients with COPD participating in the IPPB trial (190)	250 µg isoproterenol air compressor nebulizer	—	15%	—	Average increase as percent of initial FEV ₁ , (5% as percent of predicted normal FEV ₁)
150 patients with airway obstruction (191)	200 µg salbutamol or 500 µg terbutaline via metered-dose inhaler	15% (330 ml)	10% (160 ml)	—	95% confidence interval for absolute change; absolute rather than relative change preferred measure of bronchodilator response

is no consensus on how a bronchodilator response should be expressed. The three most common methods are: percent of the initial spirometric value, percent of the initial predicted baseline value, and absolute change. Expressing the change in FEV₁ as a percent of predicted FEV₁ deserves further study as it has been reported to have advantages over current methods (193). When using the percent change from the initial values as the criterion, most authorities would require at least a 12 to 15% increase in FEV₁ from the baseline value as necessary to define a meaningful response. Increments of less than 8% (or of less than 150 ml) are likely to be within measurement variability (191, 192). One should interpret improvement in an individual subject only if the percent change and absolute change in FEV₁ or VC are clearly beyond the expected variability of the measurement during a single testing session. A patient may respond to long-term bronchodilator therapy even though a bronchodilator response is not seen in a single laboratory testing session.

The FEF_{25-75%} is a highly variable spirometric test, in part because of its dependence on FVC, which increases with expiratory time with obstruction. If FVC changes, postbronchodilator FEF_{25-75%} is not comparable with that measured prebronchodilator. Volume adjustment of FEF_{25-75%} has been used to deal with this issue (194, 195). At least two studies have assessed the utility of FEF_{25-75%}. The results were disappointing, with only 8% of asthmatics (195) and 7% of patients with chronic obstructive pulmonary disease (COPD) (196) identified by FEF_{25-75%} criteria alone as outside the expected range. Tests such as the FEV₁/VC ratio and flow rates mea-

sured at some fraction of the VC may also be misleading in assessing bronchodilator response if expiratory time changes are not considered and if flows are not measured at the same volume below TLC.

Current published criteria and the Workshop recommendations for determining bronchodilator response are given in table 12.

Interpretation of Lung Function Tests in Clinical Practice

Pulmonary function tests may be used to address major issues in clinical case management. These include describing dysfunction and assessing its severity, explaining it in terms of diagnosis, establishing prognosis, planning management, and assessing trends over time, including changes after treatment. Pulmonary function tests may also be used to identify an abnormality in subjects without a known pulmonary disorder, as in preoperative assessments, in routine health status evaluations, and in clinical screening. Finally, pulmonary function tests are increasingly requested as

part of health assessment on behalf of a third party (e.g., an insurance company or a governmental agency) where the clinician is not in his or her usual patient advocacy role and the subject or patient is, consequently, wary. In each of these situations, the question asked of the pulmonary function laboratory is quite different. Ideally, interpretations of pulmonary function tests should depend on the purpose of the tests and, when performed on patients with known disease, should be oriented to answering the specific question of the clinician ordering the procedure. Tests interpreted without clinical information will be limited in their clinical utility and the interpretation will usually represent only a refined description of the data obtained.

The first step in interpreting a lung function test is to evaluate the quality of the study. If there are reasons to suspect the quality of the test, avoid specific diagnostic statements. Dysfunction discovered under these circumstances should indicate only the need for more definitive testing.

TABLE 12
RECOMMENDED CRITERIA FOR RESPONSE TO
A BRONCHODILATOR IN ADULTS

Organization	FVC (%)	FEV ₁ (%)	FEF _{25-75%} (%)	Comments
American College of Chest Physicians (197)	15-25	15-25	15-25	% of baseline in at least two of three tests
Intermountain Thoracic Society (19)	15	12	45	% of baseline
ATS (current document)	12	12	—	% of baseline and an absolute change of 200 ml

PATTERNS OF DYSFUNCTION

Certain patterns of physiologic abnormalities can be recognized, and although they are seldom if ever pathognomonic for a specific disease entity, the types of clinical illnesses most likely to produce the observed set of physiologic disturbances can be pointed out. Regardless of the extent of testing, the most important point with regard to pattern recognition is the need to be conservative with respect to suggesting a specific diagnosis for the underlying disease process based only on pulmonary function abnormalities. Recognition of characteristic patterns of dysfunction depends a great deal on the comprehensiveness of the lung function evaluation. However, even with only spirometric results, one can determine whether the pattern is compatible with obstruction with or without a reduction in VC. A reduced VC without evidence of expiratory slowing is a nonspecific finding. There was controversy among Workshop participants about using the term "restrictive" when VC is low. The majority thought it was acceptable to interpret the finding as indicating a "restrictive type of ventilatory impairment," or a "restrictive ventilatory defect" while recognizing that it does not necessarily indicate restrictive lung disease. Others argued the interpretation should be descriptive only, i.e., simply noted as "reduced vital capacity" or "nonobstructive defect," and call for further testing, including lung volumes, to clarify its nature.

The VC, FEV₁, and FEV₁/VC ratio are the basic parameters used to interpret spirometry. Although FVC is often used in place of VC it is preferable to use the largest VC, whether obtained on inspiration (IVC), slow expiration (EVC), or forced expiration (FVC), for clinical testing. The FVC is usually reduced more than IVC or EVC in airflow obstruction. Limiting primary interpretation of spirometry to three variables avoids the problem of simultaneously examining a multitude of measurements to see if any abnormalities are present, a procedure that will lead to an inordinate number of "abnormal" tests among the healthiest groups in a population (198, 199). Even when the rate of abnormality for any single test is only 5%, the frequency of at least one abnormal test was shown to be 10% in 251 healthy subjects when FEV₁, FVC, and FEV₁/FVC ratio were examined and increased to 24% when a battery of 14 different measurements were analyzed (198).

The FEV₁/VC ratio is the most important measurement for distinguishing an obstructive impairment. Expiratory flow measurements other than the FEV₁ and FEV₁/VC should be considered only after determining the presence and clinical severity of obstructive impairment using the basic values mentioned above. When FEV₁ and the FEV₁/VC ratio are within the expected range, abnormalities in flow occurring late in the maximal expiratory flow-volume (MEFV) curve should not be graded as to severity, and, if mentioned, interpretation of their clinical significance should be guarded. In the presence

of a borderline value for FEV₁/FVC, however, they may help confirm the presence of airway obstruction. The same is true for average flows such as FEF_{25-75%}. Even when used in this limited way, the wide variability of these tests in healthy subjects must be taken into account in their interpretation.

One should be cautious in interpreting obstructive dysfunction when the FEV₁ and VC are both above predicted even when the FEV₁/VC ratio is below the lower limit of normal since this pattern is sometimes seen in healthy subjects, including athletes. Tests other than spirometry, including lung volumes, diffusing capacity, and blood gas determinations allow amplifying statements on the overall pattern of the dysfunction observed during spirometry.

LOWER LIMITS OF "NORMAL" IN CLINICAL INTERPRETATION

Lower limits of normal are often used in clinical practice without thoughtful reflection about their inherent variability (5, 180, 181, 200-207) or their implications (5, 182). (See also sections DISTRIBUTION AND LOWER LIMITS OF NORMAL, DETERMINATION OF THE NORMAL RANGE, and CONCEPTUAL ISSUES CONCERNING NORMALITY AND THE LIMITS OF NORMAL.) Although clinical interpretation is usually straightforward when a pulmonary function result is well above or below a "lower limit of normal," this is not so when a measured value falls close to the "lower limit of normal." Predicting the presence or absence of disease requires knowledge about the distribution of dysfunction in various disease states and the prior probability of disease. For example, consider the meaning of a spirometric study that shows FEV₁ values and other expiratory flow rates to be just above the lower limit of normal. If the patient were a healthy male who sought medical assistance because he was disqualified for life insurance on the basis of his spirometry, it would be appropriate to interpret his spirometry as within normal limits. If, in contrast, the same data were obtained from a smoker with complaints of intermittent coughing and occasional wheezing, it would be appropriate to suggest that the study is consistent with mild obstructive dysfunction, although it could also represent a variant of normal. In both of these instances, computer printouts, or robotic physician interpretation that simplistically declare the results to be "normal" or "abnormal" on the basis of whether the observed values fall to one side or the other of a single number, could give information that does not perform a useful service to the patient. One suggestion for minimizing the problems of overly simplistic use of the lower limits of "normal" in the interpretation of lung function tests is use of terms such as "unusually low" rather than "abnormal" for tests close to the lower limit of normal.

ASSESSING SEVERITY

Severity scores are most appropriately derived from studies that relate pulmonary function

test values to independent indices of performance such as ability to work and function in daily life, morbidity, and prognosis (208-212). For instance, in general, ability to work and to function in daily life relates to one's pulmonary function level. FVC and/or FEV₁, which also relate to maximal \dot{V}_{O_2} and work effort, are used in several published systems to rate impairment (208, 209). Pulmonary function level is also associated with morbidity; those with lower function having more respiratory complaints (212). Lung function level is also associated with prognosis, including a fatal outcome from heart as well as lung disease (213, 214) even in patients who have never smoked (215). In the Framingham study, vital capacity was a major independent predictor of cardiovascular morbidity and mortality (213, 214). In several occupational cohorts FEV₁ and FEV₁/FVC were independent predictors of all cause or respiratory disease mortality (216-218). In addition, a meta-analysis of mortality in six surveys in various U.K. working populations showed that the risk of dying of COPD was related to FEV₁ level. In comparison to those whose FEV₁ at initial examination was within 1 SD of average, those whose FEV₁ was more than 2 SD below average were 12 times more likely to die of COPD, over 10 times more likely to die of non-neoplastic respiratory disease, and more than twice as likely to die of vascular disease over a 20-yr follow-up period (219). A reduced FEV₁ also carries a 4- to 5-fold excess risk of lung cancer mortality (adjusted for cigarette smoking) (220, 221). Although there is good evidence that FEV₁ correlates with the severity of symptoms and prognosis in many circumstances (208, 211, 212, 219), the correlations do not allow one to accurately predict symptoms or prognosis for individual patients.

In clinical practice, predicted values are also used to grade severity. The severity of the spirometric abnormality is usually based on the actual or percent predicted FEV₁ in the case of obstructive disorders or on VC in nonobstructive disorders. An example of an algorithm sometimes employed for grading severity when nothing is known about the clinical question being asked is shown in table 13. It is intended only as an example and not as a standard. Its approach is based as much on clinical impression as on objective data. Although clinical experience has always played a major role in assessing severity, it can be enhanced by more exact methods, and physicians should probably view arbitrary severity scoring systems with caution.

Comments on the severity or significance of any abnormality depend on the circumstances under which a test is obtained. For example the assessment of severity of obstruction illustrated in table 13 may be relevant to a patient with tracheal stenosis whose obstruction could be life-threatening and yet classified as only mildly reduced by this scheme.

The VC has some relationship to the extent of loss of functioning lung parenchyma

TABLE 13
EXAMPLE OF CRITERIA FOR ASSESSING THE SEVERITY OF ABNORMALITIES*

A. Normal: The test is interpreted as "within normal limits" if both the VC and the FEV ₁ /VC ratio are in the normal range.	
B. Obstructive abnormality: This is interpreted when the FEV ₁ /VC ratio is below the normal range. The severity of the abnormality might be graded as follows:	
"May be a physiological variant"	% Pred FEV ₁ ≥ 100
"Mild"	% Pred FEV ₁ < 100 and ≥ 70
"Moderate"	% Pred FEV ₁ < 70 and ≥ 60
"Moderately severe"	% Pred FEV ₁ < 60 and ≥ 50
"Severe"	% Pred FEV ₁ < 50 and ≥ 34
"Very severe"	% Pred FEV ₁ < 34
C. Restrictive abnormality: This is most reliably interpreted on the basis of TLC. If this is not available, one may interpret a reduction in the VC without a reduction of the FEV ₁ /VC ratio as a "restriction of the volume excursion of the lung." The severity of the abnormality might be graded as follows:	
Based on the TLC	
"Mild"	% Pred TLC < LLN but ≥ 70
"Moderate"	% Pred TLC < 70 and ≥ 60
"Moderately severe"	% Pred TLC < 60
Based on spirometry	
"Mild"	% Pred VC < LLN but ≥ 70
"Moderate"	% Pred VC < 70 and ≥ 60
"Moderately severe"	% Pred VC < 60 and ≥ 50
"Severe"	% Pred VC < 50 and ≥ 34
"Very severe"	% Pred VC < 34

Definition of abbreviation: LLN = lower limit of normal.

* This schema was contributed by Burrows and Lebowitz. It has been in use in the lung function laboratory at the Health Sciences Center in Tucson, Arizona for clinical purposes. It is intended only as an example of a transparent schema for assessing severity. Other schema may be acceptable as well. More work is required before any schema can be adopted as a standard. Note: All statements regarding severity should be accompanied by a disclaimer such as "as assessed by spirometry" or "physiologic assessments of severity may differ from clinical assessments."

TABLE 14
CHANGE IN SPIROMETRIC INDICES OVER TIME

	Percent Changes Required to be Significant		
	FVC	FEV ₁	FEF ₂₅₋₇₅
Within a day (222)			
Normal subjects	≥ 5	≥ 5	≥ 13
Patients with COPD	≥ 11	≥ 13	≥ 23
Week to week (222)			
Normal subjects	≥ 11	≥ 12	≥ 21
Patients with COPD	≥ 20	≥ 20	≥ 30
Year to year (69)	≥ 15	≥ 15	

in many nonobstructive lung disorders. It is also of some use in assessing respiratory muscle involvement in certain neuromuscular diseases. Here again, however, the VC may be only slightly impaired in diffuse interstitial diseases of sufficient severity to lead to marked loss of diffusing capacity and severe blood gas abnormalities, and a relatively small decrement in VC may indicate the onset of a severe respiratory problem in patients with a rapidly progressive neuromuscular disease.

The FEV₁/VC ratio should not be used in isolation to determine the severity of an obstructive disorder. Both the FEV₁ and VC may decline with progression of disease, and an FEV₁/VC of 0.5/1.0 indicates more impairment than one of 2.0/4.0, though both yield a ratio of 50%. Systems that use FEV₁/FVC to grade the severity of obstruction must deal with the effect of total expiratory time on FVC and FEV₁/FVC (19).

CHANGES IN SPIROMETRY OVER TIME

Reliance should be placed on FEV₁ and VC for examining changes over time as they are the only spirometric variables that will consistently and correctly reflect the direction of the change in overall ventilatory function. Even using these simple tests, it is never easy to determine whether a change is "real" or only a result of test variability. All lung function measurements tend to be more variable when made weeks to months apart than when repeated at the same test session or even daily (222, 223). Changes should therefore be interpreted cautiously. It is more likely that a real change has occurred when there are a series of tests that show a consistent trend. As shown in table 14 significant changes, whether statistical or biologic, vary by parameter, time period, and the type of patient. For FVC and VC in healthy subjects, within-day change of 5% or more, between-weeks changes of 11 to

12% or more, and yearly change of 15% or more were generally thought by the Workshop to be clinically important.

The clinician seeing the patient can often interpret results of serial tests in a useful manner, not reproducible by any simple algorithm. For example, seemingly stable tests may prove very reassuring in a patient receiving therapy for a disease that is otherwise rapidly progressive. The same tests may be very disappointing if one is treating a disorder that is expected to improve dramatically with the therapy prescribed. Depending on the clinical situation, statistically insignificant trends in function may be very meaningful to the clinician. The greatest errors occur when one attempts to interpret serial changes in subjects without disease because test variability will usually far exceed the true annual decline, and reliable rates of change for an individual subject cannot be calculated without prolonged follow-up (69). Thus, in subjects with "normal" lung function, changes in VC or FEV₁ over 1 yr should probably exceed 15% (table 14) before any confidence can be given to the opinion that a meaningful year-to-year change has occurred.

Recommendations

Overall

TECHNICAL ISSUES

Although technical sources of variation in spirometry have been fully dealt with in other documents, it was considered important to reemphasize their key role, particularly in relation to the following points.

1. Laboratory directors should be constantly on guard to maintain the precision and accuracy of the measurements made in their laboratories and should be aware of the potential sources of technical variation. Quality control includes strict adherence to ATS guidelines for equipment performance and calibration.
2. Attention should be given to the spirometer temperature where the tests are performed. Temperature-related errors will be reduced when the spirometer temperature is between 17° and 40° C.
3. Computer calculations should be validated at the time equipment is purchased and after any changes are made in software or hardware.

BIOLOGIC VARIATION AND STATISTICAL ISSUES

1. Laboratory directors should be aware of the biologic sources of within- and between-individual variation in order to optimize the application of lung function tests to a particular patient. A number of within-individual sources of variation fall within the domain and control of the laboratory, whereas between-individual sources of variation are important in selecting appropriate reference values.
2. Environmental sources of variation pertinent to a given patient are more likely to be known to the referring clinician than to

the laboratory director and should be used in evaluating the clinical pertinence of a given lung function report. Laboratory directors should request this information from clinicians.

- Those who generate and report lung function tests should be aware of the strengths and weaknesses of the statistical techniques used to generate the prediction values used for interpretation. Laboratory directors and chest physicians should also be aware of the strengths and limitations of the statistical concepts of normality.

Selecting Reference Values

GENERAL CONSIDERATIONS

- Because of unexplained differences between published reference values, no one set of reference values is likely to be applicable to all laboratories and all clientele under all circumstances. The choice of reference values should be a matter of careful consideration by laboratory directors. It should not be left to the judgment of manufacturers of automated equipment.
- Laboratories should indicate the source of reference values on their reports.
- Ideally, reference values should be based on data obtained using equipment and procedures that conform to current ATS recommendations. The prediction equations listed in tables 3 and 4 and published since 1981 conform to current ATS recommendations.

EPIDEMIOLOGIC CONSIDERATIONS

- Reference values should not come from studies based on hospital patients.
- Reference values for most clinical applications should be based on cross-sectional studies.
- Subjects used to generate reference values should be free of respiratory symptoms and disease. It is preferable to choose reference values for men and women from the same population source.
- Reference equations based on nonsmokers should be used for most clinical applications. The problems in making adjustments for the biologic effects of smoking lead to the recommendation that such adjustments should not be part of routine clinical interpretation. Such adjustments may, occasionally, be made to address specific questions.
- Altitude may be important in the selection of reference values for flow rates and DLCO.

STATISTICAL CONSIDERATIONS

- Prediction equations for adults should include age and height as independent variables. Usually, separate equations are used for men and women.
- Linear equations perform adequately for adults though they may overpredict in young adults and underpredict in the elderly.
- Prediction equations should come from studies that present lower limits of normal or present information from which such lower limits can be calculated.
- Reference equations should, in general, not

be extrapolated for ages or heights beyond those covered by the data that generated them. If, for example, one calculates a predicted FEV₁ for an 85-yr-old person from prediction equations based on a population younger than 65 yr of age, the report should contain a cautionary statement.

- The choice of reference values should consider the ethnic origins of the clientele of the laboratory. Although it is preferable to use equations based on the ethnic origins of the subject being tested, this is not always possible or practical. For instance, if a laboratory only occasionally serves subjects of a particular ethnic group, it is acceptable to adjust for ethnic differences by using a scaling factor as suggested in table 9.

LOWER LIMITS OF NORMAL

- Normal ranges should be based on calculated fifth percentiles. Estimates of fifth percentiles based on the SEE are acceptable for indices with distributions that are close to Gaussian.
- Lower limits of normal are variable and, therefore, should not be considered as arbitrary limits that correctly classify all patients into normal and abnormal groups. Patient values that lie close to lower limits should be interpreted with caution.
- The use of 80% of predicted for a lower limit of normal for adult pulmonary function parameters is not recommended. This criterion works only for average persons and for a limited number of parameters. It creates major errors when applied to FEF_{25-75%} and the instantaneous flows. Fixed percent of predicted values may be acceptable in children.
- In adults, it is not acceptable to use a fixed FEV₁/FVC ratio as a lower limit of normal.

OTHER CONSIDERATIONS

- It is preferable for North American laboratories to select reference value studies based on North American populations and European laboratories studies based on European populations because an important portion of the variation between population studies remains unexplained.
- To assist in the choice of reference values, it may be useful to make an empirical assessment of how different equations relate to measurements made in 20 to 40 healthy subjects typical of the laboratory's clientele. If the distribution of these measurements is, on the whole, within the range predicted, the choice is probably suitable. If this is not the case, the differences may be due to the laboratory (apparatus, technician, procedure) or it may be that the reference values are inappropriate for the laboratory's clientele. Both possibilities should be considered.

Recommendations for Interpretation

OVERALL CLINICAL INTERPRETATION

- Because interpretation of the lung function tests of an individual patient is best made in light of the clinical question asked of the tests, the clinician requesting the test

should frame this question as precisely as possible. Likewise, the laboratory director responsible for seeing that the tests are carried out should insist that the clinical question be included in the requisition.

- Interpreters of lung function tests should be conservative in suggesting a specific diagnosis based only on pulmonary function abnormalities.
- Borderline "normal" values should be interpreted with caution. Such interpretations should, when possible, use clinical information in the decisions as to what is normal and what is abnormal.
- The first step in interpretation is to evaluate and comment on the quality of the tests.
- The number of test indices (e.g., FVC, FEV₁, etc.) used in interpretation should be limited to avoid an excessive number of false positive results.
- The primary guides for spirometry interpretation should be VC (slow or forced), FEV₁, and FEV₁/VC.
- Tests performed on children are best interpreted by those familiar with pulmonary function in children.

CONCERNING AIRWAY OBSTRUCTION

- FEV₁/VC should be the primary guide for distinguishing obstructive from nonobstructive patterns.
- Instantaneous and mid flows may be used to confirm the presence of airway obstruction in the presence of a borderline FEV₁/VC.
- FEF_{25-75%} and the instantaneous flows should not be used to diagnose small airway disease in individual patients.
- The pattern of a low FEV₁/VC ratio and greater than average VC and FEV₁ should be recognized as one that may occur in healthy individuals.
- The severity of airway obstruction should be based on FEV₁ rather than FEV₁/VC.
- Abnormalities in instantaneous flows and FEF_{25-75%} should not be graded as to severity when FEV₁ and FEV₁/VC are within the normal range.

CONCERNING BRONCHODILATOR RESPONSE

- VC (forced or slow) and FEV₁ should be the primary indices used to judge bronchodilator response. Total expiratory time should be considered when using FVC to assess bronchodilator response since FVC increases in obstructed patients as expiratory time increases.
- A 12% increase, calculated from the prebronchodilator value, and a 200-ml increase in either FVC or FEV₁ are reasonable criteria for a positive bronchodilator response in adults.
- FEF_{25-75%} and the instantaneous flows should be considered secondarily in evaluating bronchodilator response. If used, they must be volume-adjusted or the effect or changing FVC must be dealt with in the interpretation.
- Ratios such as FEV₁/VC should not be used to judge bronchodilator response.

5. Patients may respond to bronchodilator therapy even though a bronchodilator response is absent in a laboratory test.

CONCERNING RESTRICTION

1. The diagnosis of a restrictive lung abnormality is based on a reduced TLC. A reduced VC in the presence of a normal FEV₁/VC may be used to suggest but not diagnose the presence of restriction.
2. The severity of restriction should be based on TLC. If VC is used to infer the presence of restriction, severity may be based on VC.

This Statement was prepared by the participants of a Workshop on Lung Function Testing: Selection of Reference Values and Interpretative Strategies. The workshop participants were: MARGARET BECKLAKE, M.D., and ROBERT O. CRAPO, M.D., *Co-Chairpersons*, A. SONIA BUIST, M.D., BENJAMIN BURROWS, M.D., JACK L. CLAUSEN, M.D., ALLAN L. COATES, M.D., JOHN COTES, D.M., DOUGLAS W. DOCKERY, PH.D., REED M. GARDNER, PH.D., JOHN L. HANKINSON, PH.D., JAMES HANLEY, PH.D., ROBERT L. JOHNSON, JR., M.D., MICHAEL D. LEBOWITZ, PH.D., PAOLO PAOLETTI, M.D., RENE PESLIN, M.D., GEORGE POLGAR, M.D., PHILIP H. QUANJER, M.D., MELVYN S. TOCKMAN, M.D., SCOTT T. WEISS, M.D., M.S., MARY ELLEN B. WOHL, M.D.

References

1. Bates DV. Respiratory function in disease. 3rd ed. Philadelphia: WB Saunders, 1989.
2. Clausen JL, ed. Pulmonary function testing: guidelines and controversies. New York: Academic Press, 1982.
3. Miller A, ed. Pulmonary function tests: a guide for the student and house officer. Orlando, FL: Grune & Stratton, 1987.
4. Quanjer PhH, ed. Standardized lung function testing: report of the working party. Bull Eur Physiopathol Respir 1983; 19(Suppl 5:1-95).
5. Becklake MR. Concepts of normality applied to the measurement of lung function. Am J Med 1986; 80:1158-63.
6. Buist AS. Evaluation of lung function: Concepts of normality. In: Simmons DH, ed. Current pulmonology. Vol 4. New York: John Wiley and Sons, 1982; 141-65.
7. American Thoracic Society. Snowbird workshop on standardization of spirometry. Am Rev Respir Dis 1979; 119:831-8.
8. American Thoracic Society. Standardization of spirometry: 1987 update. Am Rev Respir Dis 1987; 136:1285-98.
9. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique. Am Rev Respir Dis 1987; 136:1299-307.
10. Gardner RM, Clausen JL, Epler G, Hankinson JL, Permutt S, Plummer AL. Pulmonary function laboratory personnel qualifications. Am Rev Respir Dis 1986; 134:623-4.
11. Gardner RM, Clausen JL, Crapo RO, *et al*. Quality assurance in pulmonary function laboratories. Am Rev Respir Dis 1986; 134:625-7.
12. Gardner RM, Clausen JL, Cotton DJ, Crapo RO, Hankinson JL, Johnson RL. Computer guidelines for pulmonary laboratories. Am Rev Respir Dis 1986; 134:628-9.
13. Quanjer PhH, Helms P, Bjure J, Gaultier C. Standardization of lung function tests in paediatrics. Eur Respir J 1989; 2(Suppl 4:121S-264S).
14. Ferris BG Jr, ed. Epidemiology standardization project. Part 2. Am Rev Respir Dis 1978; 118:1-120.
15. Pulmonary terms and symbols: a report of the ACCP-ATS Joint Committee on Pulmonary Nomenclature. Chest 1975; 67:583-93.
16. Jay F, ed. IEEE standard dictionary of electrical and electronic terms. 3rd ed. New York: Institute of Electrical and Electronics Engineers, Inc, 1984.
17. Nelson SB, Gardner RM, Crapo RO, Jensen RL. Performance evaluation of contemporary spirometers. Chest 1990; 97:288-97.
18. Pistelli G, Carmignani G, Paoletti P, *et al*. Comparison of algorithms for determining the end point of the forced vital capacity maneuver. Chest 1987; 91:100-5.
19. Morris AH, Kanner RE, Crapo RO, Gardner RM. Clinical pulmonary function testing: a manual of uniform laboratory procedures. 2nd ed. Salt Lake City, UT: Intermountain Thoracic Society, 1984.
20. Cotes JE. Lung function: assessment and application in medicine. 4th ed. Oxford: Blackwell Scientific Publications, 1979.
21. Wilson AF, ed. Pulmonary function testing, indications and interpretations. Orlando, FL: Grune & Stratton, 1985.
22. Burrows B, Knudson RJ, Quan SF, Kettel LJ. Respiratory disorders: a pathophysiologic approach. Chicago: Year Book Medical Publishers, 1983.
23. Enright PL, Hyatt RE. Office spirometry: a practical guide to the selection and use of spirometers. Philadelphia: Lea & Febiger, 1987.
24. Allen SM, Hunt B, Green M. Fall in vital capacity with posture. Br J Dis Chest 1985; 79:267-71.
25. Pierson DJ, Dick NP, Petty TL. A comparison of spirometric values with subjects in standing and sitting positions. Chest 1976; 70:17-20.
26. Blair E, Hickam JB. The effect of change in body position on lung volume and intrapulmonary gas mixing in normal subjects. J Clin Invest 1955; 34:383-9.
27. Townsend MC. Spirometric forced expiratory volumes measured in the standing versus the sitting posture. Am Rev Respir Dis 1984; 130:123-4.
28. Glindmeyer H. Predictable confusion. J Occup Med 1981; 23:845-9.
29. Melissinos CG, Mead J. Maximum expiratory flow changes induced by longitudinal tension on trachea in normal subjects. J Appl Physiol 1977; 43:537-44.
30. Liistro G, Stanescu D, Doms G, Rodenstein D, Veriter C. Head position modifies upper airway resistance in men. J Appl Physiol 1988; 64:1285-8.
31. Krowka MJ, Enright PL, Rodarte JR, Hyatt RE. Effect of effort on measurement of forced expiratory volume in one second. Am Rev Respir Dis 1987; 136:829-33.
32. Ingram RH Jr, Schilder DP. Effect of thoracic gas compression on the flow-volume curve of the forced vital capacity. Am Rev Respir Dis 1966; 94:56-63.
33. Sadoul P. Mesure de la capacité vitale et des débits maximaux. In: Denolin H, Sadoul P, Orié NGM, eds. L'exploration fonctionnelle pulmonaire. 2nd partie. Paris: Flammarion, 1971; 389.
34. Van de Woestijne KP, Afschrift M. Airway dynamics during forced expiration in patients with chronic obstructive lung disease. In: Orié NGM, Van der Lende R, eds. Bronchitis III. Assen: Royal Van Gorcum, 1970; 195-206.
35. Gimeno F, Berg WC, Sluiter HJ, Tammeling GJ. Spirometry-induced bronchial obstruction. Am Rev Respir Dis 1972; 105:68-74.
36. Eisen E, Dockery DW, Speizer FE, Fay ME, Ferris BJ Jr. The association between health status and the performance of excessively variable spirometry tests in a population-based study in six U.S. cities. Am Rev Respir Dis 1987; 136:1371-6.
37. Becklake MR. Epidemiology of test failure. Br J Ind Med 1990; 47:73-4.
38. Hetzel MR. The pulmonary clock. Thorax 1981; 36:481-6.
39. Guberan E, Williams MK, Walford J, Smith MM. Circadian variation of FEV₁ in shift workers. Br J Ind Med 1969; 26:121-5.
40. Hetzel MR, Clark TJH. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 1980; 35:732-8.
41. Clark TJH, Hetzel MR. Diurnal variation of asthma. Br J Dis Chest 1977; 71:87-92.
42. McDermott M. Diurnal and weekly cyclical changes in lung airways resistance. J Physiol (Lond) 1966; 186:90.
43. De Millas H, Ulmer WT. Circadian rhythms of airways resistance in healthy subjects and patients with obstructive airways disease. Pneumologie 1971; 144:237-52.
44. Kerr HD. Diurnal variation of respiratory function independent of air quality. Arch Environ Health 1973; 26:144-52.
45. Barnes PJ. Circadian variation in airway function. Am J Med 1985; 79(Suppl 6A:5-9).
46. Barnes P, Fitzgerald G, Brown M, Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine and cortisol. N Engl J Med 1980; 303:263-7.
47. Hetzel MR, Clark TJH, Branthwaite MA. Asthma: analysis of sudden deaths and ventilatory arrests in hospital. Br Med J 1977; 1:808-11.
48. Bagg LR, Hughes DTD. Diurnal variation in peak expiratory flow in asthmatics. Eur J Respir Dis 1980; 61:298-302.
49. Halberg F. Chronobiology and the lung: implications and applications. Bull Eur Physiopathol Respir 1987; 23:529-31.
50. Lewinsohn HC, Capel LH, Smart J. Changes in forced expiratory volumes throughout the day. Br Med J 1960; 1:462-4.
51. Minette A. Contribution to the chronobiology of lung function: changes of baseline values of four lung function indices between 8h and 17h in patients with bronchitic complaints without asthmatic components. Bull Eur Physiopathol Respir 1987; 23:541-3.
52. Buist AS, Vollmer WM. The use of lung function tests in identifying factors that affect lung growth and aging. Stat Med 1988; 7:11-8.
53. Ferris BG Jr, Stoudt HW. Correlation of anthropometry and simple tests of pulmonary function. Arch Environ Health 1971; 22:672-6.
54. Hibbert ME, Lanigan A, Raven J, Phelan PD. Relation of armspan to height and the prediction of lung function. Thorax 1988; 43:657-9.
55. Schoenberg JB, Beck GJ, Bouhuys A. Growth and decay of pulmonary function in healthy blacks and whites. Respir Physiol 1978; 33:367-93.
56. Dockery DW, Ware JH, Ferris BG Jr, *et al*. Distribution of forced expiratory volume in one second and forced vital capacity in healthy, white, adult never-smokers in six U.S. cities. Am Rev Respir Dis 1985; 131:511-20.
57. Howatt WF, DeMuth GR. II. Configuration of the chest. Pediatrics 1965; 35:177-84.
58. Damon A. Negro-white differences in pulmonary function (vital capacity, timed vital capacity, and expiratory flow rate). Hum Biol 1966; 38:381-93.
59. Marcus EB, Buist AS, Curb JD, *et al*. Correlates of FEV₁ and prevalence of pulmonary conditions in Japanese-American men. Am Rev Respir Dis 1988; 138:1398-404.
60. DeGroot EG, van Pelt W, Quanjer PhH, van Zomeren BC, Borsboom GJJM. Growth of lung and thorax dimensions during the pubertal growth spurt. Eur Respir J 1988; 1:102-8.
61. Green M, Mead J, Turner JM. Variability of

- maximum expiratory flow-volume curves. *J Appl Physiol* 1974; 37:67-74.
62. Mead J. Dysanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity. *Am Rev Respir Dis* 1980; 121:339-42.
 63. Schwartz JD, Katz SA, Fegley RW, Tockman MS. Analysis of spirometric data from a national sample of healthy 6- to 24-year-olds (NHANES II). *Am Rev Respir Dis* 1988; 138:1405-14.
 64. Schwartz DJ, Katz SA, Fegley RW, Tockman MS. Sex and race differences in the development of lung function. *Am Rev Respir Dis* 1988; 138:1415-21.
 65. Becklake MR, Permutt S. Evaluation of tests of lung function for "screening" for early detection of chronic obstructive lung disease. In: Macklem PT, Permutt S, eds. *The lung in the transition between health and disease*. New York: Marcel Dekker, 1979; 345-88.
 66. Vollmer WM, Johnson LR, McCamant LE, Buist AS. Methodological issues in the analysis of lung function data. *J Chronic Dis* 1987; 40:1013-23.
 67. Vollmer WM, Johnson LR, McCamant LE, Buist AS. Longitudinal versus cross-sectional estimation of lung function decline: further insights. *Stat Med* 1988; 7:685-96.
 68. Louis TA, Robins J, Dockery DW, Spiro A III, Ware JH. Explaining discrepancies between longitudinal and cross-sectional models. *J Chronic Dis* 1986; 39:831-9.
 69. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. *Am Rev Respir Dis* 1986; 133:974-80.
 70. Van Pelt W, Quanjer PhH, Borboom G. Cohort effects in ventilatory function and chronic respiratory symptoms in a 12 year follow-up study (abstract). *Eur Respir J* 1989; 2(Suppl 5:3665).
 71. Weisman IM, Zeballos RH. Lower single breath carbon monoxide diffusing capacity (DL_{CO}) in black subjects compared with caucasians. *Chest* 1987; 92(Suppl:1425).
 72. National Center for Health Statistics. Body weight, stature, and sitting height: white and Negro youths 12-17 years. Washington, DC: Health Services and Mental Health Administration, 1973. (Vital and Health Statistics. Series 11, no. 126) (DHEW publication no. [HRAS]74-1608).
 73. National Center for Health Statistics. Body dimensions and proportions, white and Negro children 6-11 years. Washington, DC: Health Resources Administration, 1974. (Vital and Health Statistics. Series 11, no. 143) (DHEW publication no. [HRAS] 75-1625).
 74. National Center for Health Statistics. Forced vital capacity of children 6-11 years. Washington, DC: Public Health Service, 1978. (Vital and Health Statistics. Series 11, no. 164) (DHEW publication no. [PHS]78-1651).
 75. National Center for Health Statistics. Skin folds, body girths, bicromial diameter and selected anthropometric indices of adults. Washington, DC: Public Health Service, 1970. (Vital and Health Statistics. Series 11, no. 35) (DHEW publication no. [PHS] 100-11-35).
 76. National Center for Health Statistics. Selected body measurements of children 6-11 years. Washington, DC: Health Services and Mental Health Administration (Vital and Health Statistics. Series 11, no. 123) (DHEW publication no. [HSM]73-1605).
 77. Van de Wal BW, Erasmus LD, Hechter R. Stem and standing heights in Bantu and white South Africans: their significance in relation to pulmonary function values. *S Afr Med J* 1971; 45(Suppl: 568-70).
 78. Woolcock AJ, Coleman MH, Blackburn CRB. Factors affecting normal values for ventilatory lung function. *Am Rev Respir Dis* 1972; 106:692-709.
 79. Cotes JE, Anderson HR, Patrick JM. Lung function and the response to exercise in New Guineans: role of genetic and environmental factors. *Philos Trans R Soc Lond [Biol]* 1974; 268:349-61.
 80. Miller GJ, Saunders MJ, Gilson RJ, *et al*. Lung function of healthy boys and girls in Jamaica in relation to ethnic composition, test exercise performance, and habitual physical activity. *Thorax* 1977; 32:486-96.
 81. Oscherwitz M, Edlavitch SA, Baker TR, *et al*. Differences in pulmonary functions in various racial groups. *Am J Epidemiol* 1972; 96:319-27.
 82. Mueller WH, Yen F, Soto P, *et al*. A multinational Andean genetic and health program. VIII. Lung function changes with migration between altitudes. *Am J Phys Anthropol* 1979; 51:183-95.
 83. Brown P, Sadowsky D, Gajdusek DC. Ventilatory lung functions studies in Pacific Island Micronesians. *Am J Epidemiol* 1978; 108:259-65.
 84. Myers J. Differential ethnic standards for lung function or one standard for all? *S Afr Med J* 1984; 65:768-72.
 85. Steinberg M, Becklake MR. Socio-environmental factors and lung function. *S Afr Med J* 1986; 70:270-4.
 86. Burrows B, Taussig LM. As the twig is bent, the tree inclines (perhaps). *Am Rev Respir Dis* 1980; 122:813-6.
 87. Burrows B, Knudson RJ, Lebowitz MD. The relationship of childhood respiratory illness to adult obstructive airway disease. *Am Rev Respir Dis* 1977; 115:751-60.
 88. Bertrand JM, Riley P, Popkin JA, Coates A. The long term pulmonary sequelae of prematurity: the role of familial airway hyperreactivity and the respiratory distress syndrome. *N Engl J Med* 1985; 312:742-5.
 89. U.S. Department of Health and Human Services. The health consequences of smoking: chronic obstructive lung disease, a report of the Surgeon General. Rockville, MD: Public Health Service Office on Smoking and Health, 1984.
 90. Kryger M, Aldrich F, Reeves JT, Grover RF. Diagnosis of airflow obstruction at high altitude. *Am Rev Respir Dis* 1978; 117:1055-8.
 91. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981; 123:659-64.
 92. Goldman HI, Becklake MR. Respiratory function tests. Normal values at median altitudes and the prediction of normal results. *Am Rev Tuberc* 1959; 79:457-67.
 93. Gautier H, Peslin R, Grassino A, *et al*. Mechanical properties of the lungs during acclimatization to altitude. *J Appl Physiol* 1982; 52:1407-15.
 94. Mansell A, Powles A, Sutton J. Changes in pulmonary PV characteristics of human subjects at an altitude of 5366 m. *J Appl Physiol* 1980; 49: 79-83.
 95. Jaeger JJ, Sylvester JT, Cymerman A, *et al*. Evidence for increased intrathoracic fluid volume in man at high altitude. *J Appl Physiol* 1979; 47:670-6.
 96. Frisancho AR. Functional adaptation to high altitude hypoxia. *Science* 1975; 187:313-9.
 97. Heath D, Williams DR. The lung at high altitude. *Invest Cell Pathol* 1979; 2:147-56.
 98. Lippmann M. Health significance of pulmonary function responses to irritants. *J Air Pollut Cont Assoc* 1988; 38:881-7.
 99. Goldsmith JR. Effects on human health. In: Stern A, ed. *Air pollution*. Vol VI. New York: Academic Press, 1986; 391-463.
 100. Committee on the Epidemiology of Air Pollutants. *Epidemiology and air pollution*. Washington, DC: National Academy Press, 1985.
 101. Lippmann M. Health effects of ozone: a critical review. *J Air Pollut Cont Assoc* 1989; 39:672-95.
 102. Shy CM. Health effects of acid aerosols. Review, discussion and summary of epidemiological studies. *Environ Health Perspect* 1989; 79:187-90.
 103. Linn WS, Theodore G, Venet TG, *et al*. Respiratory effects of sulfur dioxide in heavily exercising asthmatics. *Am Rev Respir Dis* 1983; 127: 278-83.
 104. Department of Health, Education and Welfare. The health consequences of involuntary smoking: a report from the Surgeon General. Washington, DC: USGPO, 1986. (DHHS publication no. [CDC]87-8398).
 105. Fielding JE, Phenow KJ. Health effects of involuntary smoking. *N Engl J Med* 1988; 319: 1452-60.
 106. Spitzer WO, Lawrence V, Dales R, *et al*. Links between passive smoking and disease: a best evidence synthesis. *Clin Invest Med* 1990; 13:17-42.
 107. Lebowitz MD, Quackenboss JJ. The effects of environmental tobacco smoke on pulmonary function. *Int Arch Environ Health* 1989; 44(Suppl: 147-52).
 108. Masi M, Hanley JA, Ernst P, Becklake MR. Environmental exposure to tobacco smoke and lung function in young adults. *Am Rev Respir Dis* 1988; 138:296-9.
 109. Martinez FD, Antognoni G, Macri F, *et al*. Parental smoking enhances bronchial responsiveness in nine-year-old children. *Am Rev Respir Dis* 1988; 138:518-23.
 110. Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. Part I. *Am Rev Respir Dis* 1987; 136:1486-508.
 111. Samet JM, Marbury MC, Spengler JD. Health effects and sources of indoor air pollution. Part II. *Am Rev Respir Dis* 1988; 137:221-42.
 112. Cotes JE, Steel J. *Work related lung disorders*. Oxford: Blackwell Scientific Publications, 1987; 436.
 113. Becklake MR. Occupational exposures: evidence of a causal association with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1989; 140:585-91.
 114. Chan-Yeung M, Lam S. Occupational asthma. *Am Rev Respir Dis* 1986; 133:686-703.
 115. Lebowitz MD. The relationship of socio-environmental factors to the prevalence of obstructive lung diseases and other chronic conditions. *J Chronic Dis* 1977; 30:599-611.
 116. Viegi G, Paoletti P, Prediletto R, *et al*. Prevalence of respiratory symptoms in an unpolluted area of northern Italy. *Eur Respir J* 1988; 1:311-8.
 117. Polgar G, Weng TR. The functional development of the respiratory system: from the period of gestation to adulthood. *Am Rev Respir Dis* 1979; 120:625-95.
 118. Polgar G, Promodhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: W B Saunders, 1971; 272.
 119. Quanjer PH, Stocks J, Polgar G, Wise ME, Karlberg J, Borsboom G. Compilation of reference values for lung function measurements in children. *Eur Respir J* 1989; 2(Suppl 4:184S-261S).
 120. DeGroot EG, Quanjer PH, Wise ME, van Zomeren BC. Changing relationships between stature and lung volumes during puberty. *Respir Physiol* 1986; 65:139-53.
 121. Cole TJ. Linear and proportional regression models in the prediction of ventilatory function. *J R Stat Soc [A]* 1975; 138:297-338.
 122. Schrader PC, Quanjer PhH, van Zomeren BC, Wise ME. Changes in the FEV₁-height relationship during pubertal growth. *Bull Eur Physiopathol Respir* 1984; 20:381-8.
 123. Seely JE, Guzman CA, Becklake MR. Heart and lung function at rest and during exercise in adolescence. *J Appl Physiol* 1974; 36:34-40.

124. Tanner JM. Growth at adolescence, with a general consideration of the effects of hereditary and environmental factors upon growth and maturation from birth to maturity. 2nd ed. Oxford: Blackwell, 1978.
125. Simon G, Reid L, Tanner JM, Goldstein H, Benjamin B. Growth of radiologically determined heart diameter, lung width, and lung length from 5-19 years, with standards for clinical use. *Arch Dis Child* 1972; 47:373-81.
126. Dockery DW, Berkey CS, Ware JH, Speizer FE, Ferris BG Jr. Distribution of forced vital capacity and forced expiratory volume in one second in children 6 to 11 years of age. *Am Rev Respir Dis* 1983; 128:405-12.
127. Rea H, Becklake MR, Ghezzi H. Lung function changes as a reflection of tissue aging in young adults. *Bull Eur Physiopathol Respir* 1982; 18:5-19.
128. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. *Am Rev Respir Dis* 1969; 99:696-702.
129. Smyth RJ, Chapman KR, Rebeck AS. Maximal inspiratory and expiratory pressures in adolescents: normal values. *Chest* 1984; 86:568-72.
130. Wagner JS, Hibbert ME, Landau LI. Maximal respiratory pressures in children. *Am Rev Respir Dis* 1984; 129:873-5.
131. Wilson SH, Cooke NT, Edwards RHT, Spiro SG. Predicted normal values for maximal respiratory pressures in Caucasian adults and children. *Thorax* 1984; 39:535-8.
132. Cook CD, Mead J, Orzalesi MM. Static volume-pressure characteristics of the respiratory system during maximal efforts. *J Appl Physiol* 1964; 19:1016-22.
133. Gaultier C, Zinman R. Maximal static pressures in healthy children. *Respir Physiol* 1983; 51:45-61.
134. Leech JA, Ghezzi H, Stevens D, Becklake MR. Respiratory pressures and function in young adults. *Am Rev Respir Dis* 1983; 128:17-23.
135. Schrader PC, Quanjer PH, Olivier JCW. Respiratory muscle force and ventilatory function in adolescents. *Eur Respir J* 1988; 1:368-75.
136. Sharp JT, Druz WS, Balagot RC, Bandelin VR, Danon J. Total respiratory compliance in infants and children. *J Appl Physiol* 1970; 29:775-9.
137. Fagan DG. Shape changes in static V-P loops from children's lungs related to growth. *Thorax* 1977; 32:198-202.
138. Zapletal A, Paul T, Samanek M. Pulmonary elasticity in children and adolescents. *J Appl Physiol* 1976; 40:953-61.
139. Baran D, Yernault JC, Paiva M, Englert M. Static mechanical lung properties in healthy children. *Scand J Respir Dis* 1976; 57:139-47.
140. Mansell AL, Bryan AC, Levison H. Relationship of lung recoil to lung volume and maximum expiratory flow in normal children. *J Appl Physiol* 1977; 42:817-23.
141. De Troyer A, Yernault JC, Englert M, Baran D, Paiva M. Evolution of intrathoracic airway mechanics during lung growth. *J Appl Physiol* 1978; 44:521-7.
142. Turner JM, Mead J, Wohl ME. Elasticity of human lungs in relation to age. *J Appl Physiol* 1968; 25:664-71.
143. Knudson RJ, Clark DF, Kennedy TC, Knudson DL. Effect of aging alone on mechanical properties of the normal adult human lung. *J Appl Physiol* 1977; 43:1054-62.
144. Cotes JE, Dabbs JM, Hall AM, Heywood C, Laurence KM. Sitting height, fat free mass and body fat as reference variables for lung function in healthy British children: comparison with stature. *Ann Hum Biol* 1979; 6:307-14.
145. Leeder SR, Swan AV, Peat JK, Woolcock AJ, Blackburn CRB. Maximum expiratory flow-volume curves in children: changes with growth and individual variability. *Bull Eur Physiopathol Respir* 1977; 13:249-60.
146. Thuribeck WM. Postnatal human lung growth. *Thorax* 1982; 37:564-71.
147. Taussig LM, Cota K, Kaltenborn W. Different mechanical properties of the lung in boys and girls. *Am Rev Respir Dis* 1981; 123:640-3.
148. Duiverman EJ, Clement J, van de Westijne KP, Neijens HP, van der Bergh ACM, Kerrebijn KF. Forced oscillation technique. Reference values for resistance and reactance over a frequency spectrum of 2-26 Hz in healthy children aged 2.3-12.5 years. *Bull Eur Physiopathol Respir* 1985; 21:171-8.
149. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. *Am Rev Respir Dis* 1983; 127:725-34.
150. Paoletti P, Pistelli G, Fazzi P, et al. Reference values for vital capacity and flow-volume curves from a general population study. *Bull Eur Physiopathol Respir* 1986; 22:451-9.
151. Lebowitz MD, Holberg CJ. Comparisons of spirometric reference values and the proportions of abnormal among male smokers and those symptomatic in a community population. *Am Rev Respir Dis* 1990; 141:1491-6.
152. Van Ganse W, Billiet L, Ferris BG. Medical criteria for the selection of normal subjects. In: Arcangeli P, Cotes JG, Cournand A, et al, eds. Normal values for respiratory function in man. *Alghero: Panminerva Medica*, 1970; 15-27.
153. Kory RC, Callahan R, Boren HG, Syner JC. The Veterans Administration-Army cooperative study of pulmonary function. I. Clinical spirometry of normal men. *Am J Med* 1961; 30:243-58.
154. De Kroon JPM, Joosting PE, Visser BF. Les valeurs normales de la capacité vitale et du volume expiratoire maximum seconde. Recherche chez les ouvriers d'une aciérie aux Pays-Bas. *Arch Mal Prof* 1964; 25:17-30.
155. Boren HG, Kory RC, Syner JC. The Veterans Administration-Army cooperative study of pulmonary function. II. The lung volume and its subdivisions in normal men. *Am J Med* 1966; 41:96-114.
156. Amrein R, Keller R, Joos H, et al. Valeurs théoriques nouvelles de l'exploration de la fonction ventilatoire de poumon. *Bull Physiopathol Respir* 1970; 6:317-49.
157. Jouasset D. Normalisation des épreuves fonctionnelles respiratoires dans les pays de la Communauté Européenne du Charbon et de l'Acier. *Poumon Coeur* 1960; 16:1145-59.
158. Miller A, Thornton JC, Warshaw R, Bernstein J, Selikoff IJ, Teirstein AS. Mean and instantaneous expiratory flows, FVC and FEV₁: prediction equations from a probability sample of Michigan, a large industrial state. *Bull Eur Physiopathol Respir* 1986; 22:589-97.
159. Miller MR, Pincock AC. Predicted values: how should we use them? *Thorax* 1988; 43:265-7.
160. Miller A. Prediction equations and "normal values." In: Miller A, ed. *Pulmonary function tests in clinical and occupational lung disease*. New York: Grune & Stratton, 1986; 197-213.
161. Oldham PD. Percent of predicted as the limit of normal in pulmonary function testing: a statistically valid approach. *Thorax* 1979; 34:569.
162. Sobol BJ, Weinheimer B. Assessment of ventilatory abnormality in the asymptomatic subject: an exercise in futility. *Thorax* 1966; 21:445-9.
163. Quanjer PH. Predicted values: how should we use them (letter). *Thorax* 1988; 43:663-4.
164. Dockery DW, Speizer FE, Ferris BG Jr, Ware JH, Louis TA, Spiro A III. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. *Am Rev Respir Dis* 1988; 137:286-92.
165. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein AS, Selikoff IJ. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. *Am Rev Respir Dis* 1983; 127:270-7.
166. Beck GJ, Doyle CA, Schachter EN. Smoking and lung function. *Am Rev Respir Dis* 1981; 123:149-55.
167. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. *Am Rev Respir Dis* 1977; 115:195-205.
168. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. London: Oxford University Press, 1976.
169. Enjeti S, Hazelwood B, Permutt S, Menkes H, Terry P. Pulmonary function in young smokers: male-female differences. *Am Rev Respir Dis* 1978; 118:667-76.
170. Higebottom T, Clark TJH, Shipley MJ, Rose G. Lung function and symptoms of cigarette smokers related to tar yield and number of cigarettes smoked. *Lancet* 1980; 1:409-11.
171. Becklake MR, Lallo U. The "healthy smoker" effect: a phenomenon of health selection. *Respiration* 1990; 57:137-44.
172. Strope GL, Helms RW. A longitudinal study of spirometry in young black and young white children. *Am Rev Respir Dis* 1984; 130:1100-7.
173. Pattishall EN, Helms RW, Strope GL. Non-comparability of cross-sectional and longitudinal estimates of lung growth in children. *Pediatr Pulmonol* 1989; 7:22-8.
174. Hibbert ME, Lannigan A, Landau LI, Phelan PD. Lung function values from a longitudinal study of healthy children and adolescents. *Pediatr Pulmonol* 1989; 7:101-9.
175. Bencowitz HC. Inspiratory and expiratory vital capacity. *Chest* 1985; 85:834-5.
176. Taussig LM, Cherniack V, Wood R, Farrell PM, Mellins RB. Standardization of lung function testing in children. Recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation. *J Pediatr* 1980; 97:668-76.
177. Zapletal A, Samanek TP. Lung function in children and adolescents: Methods and reference values. Basel-Munich: Karger, 1987.
178. Burrows B, Cline MG, Knudson RJ, Taussig LM, Lebowitz MD. A descriptive analysis of the growth and decline of the FVC and FEV₁. *Chest* 1983; 83:717-24.
179. Galen RS. The normal range: a concept in transition. *Arch Pathol Lab Med* 1977; 101:561-5.
180. Zweig MH, Beck JR, Collinsworth WL. Assessment of clinical sensitivity and specificity of laboratory tests. Proposed guideline. Philadelphia: National Committee for Clinical Laboratory Standards, 1987 (NCCLS Document GP 10-P vol. 7 no. 6).
181. Henry RJ, Reed AH. Normal values and the use of laboratory results for the detection of disease. In: Henry RJ, Cannon DC, Winkelman JW, eds. *Clinical chemistry: principles and techniques*. New York: Harper & Row, 1974; 343-70.
182. Cochrane AL, Elwood PC. Laboratory data and diagnosis (letter). *Lancet* 1969; 1:420.
183. Flenley DC. Chronic obstructive pulmonary disease. *Dis Mon* 1988; 34:537-99.
184. Mendella LA, Manfreda J, Warren CPW, Anthonisen NR. Steroid response in stable chronic obstructive pulmonary disease. *Ann Intern Med* 1982; 96:17-21.
185. Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to bronchodilator, an imperfect guide for bronchodilator therapy in chronic airflow limitation. *Arch Intern Med* 1988; 148:1949-52.
186. Lorber DB, Kaltenborn W, Burrows B. Responses to isoproterenol in a general population sample. *Am Rev Respir Dis* 1978; 118:855-61.
187. Dales RE, Spitzer WO, Tousignant P,

- Schechter M, Suissa S. Clinical interpretation of airway response to a bronchodilator: epidemiologic considerations. *Am Rev Respir Dis* 1988; 138: 317-20.
188. Watanabe S, Renzetti AD Jr, Begin R, Bigler AH. Airway responsiveness to a bronchodilator aerosol. *Am Rev Respir Dis* 1974; 109:530-7.
189. Sourk RL, Nugent KM. Bronchodilator testing: confidence intervals derived from placebo inhalations. *Am Rev Respir Dis* 1983; 128:153-7.
190. Anthonisen NR, Wright EC, and the IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986; 133:814-9.
191. Tweeddale PM, Alexander F, McHardy GJR. Short term variability in FEV₁ and bronchodilator responsiveness in patients with obstructive ventilatory defects. *Thorax* 1987; 42:487-90.
192. Eliasson O, Degraff AC Jr. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials: influence of clinical diagnosis, spirometric and anthropometric values. *Am Rev Respir Dis* 1985; 132:858-64.
193. Brand PLP, Quanjer PhH, Postma DS, *et al*. A comparison of different ways to express bronchodilator response. Part 2. *Am Rev Respir Dis* 1990; 141:A20.
194. Olsen CR, Hale FC. A method for interpreting acute response to bronchodilators from the spiograms. *Am Rev Respir Dis* 1968; 98:301-2.
195. Boggs PB, Bhat KD, Vekovius WA, Debo MS. The clinical significance of volume adjusted maximal mid expiratory flow (Iso-volume FEF_{25-75%}) in assessing airway responsiveness to inhaled bronchodilator in asthmatics. *Ann Allergy* 1982; 48: 139-42.
196. Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. *Chest* 1988; 93:541-6.
197. Committee report. Criteria for the assessment of reversibility in airways obstruction: report of the committee on emphysema, American College of Chest Physicians. *Chest* 1974; 65:552-3.
198. Vedal S, Crapo RO. False positive rates of multiple pulmonary function tests in healthy subjects. *Bull Eur Physiopathol Respir* 1983; 19:263-6.
199. Knudson RJ, Burrows B, Lebowitz MD. The maximal expiratory flow-volume curve: its use in the detection of ventilatory abnormalities in a population study. *Am Rev Respir Dis* 1976; 114:871-9.
200. Ash KO, Clark SJ, Sandberg LB, Hunter E, Woodward SC. The influences of sample distribution and age on reference intervals for adult males. *Am J Clin Pathol* 1983; 79:574-81.
201. Herrera L. The precision of percentiles in establishing normal limits in medicine. *J Lab Clin Med* 1958; 52:34-42.
202. Shulz EK, Willard KI, Rich SS, *et al*. Improved reference-interval estimation. *Clin Chem* 1985; 31:1974-8.
203. Dybkaer R. International Federation of Clinical Chemistry (IFCC)(1,2) The theory of reference values. Part 6. Presentation of observed values related to reference values. *J Clin Chem Clin Biochem* 1982; 20:841-5.
204. Elveback LR, Taylor WF. Statistical methods of estimating percentiles. *Ann NY Acad Sci* 1969; 161:538-48.
205. Linnert K. Two-stage transformation systems for normalization of reference distributions evaluated. *Clin Chem* 1987; 33:381-6.
206. Solberg HE. The theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. IFCC Scientific Committee proposed recommendations. *J Clin Chem Clin Biochem* 1983; 21:749-60.
207. Gardner MJ, Altman DG, eds. Statistics with confidence. *Br Med J* 1989; 1-140.
208. Becklake MR, Kalica AR. NHLBI workshop summary. Scientific issues in the assessment of respiratory impairment. *Am Rev Respir Dis* 1988; 137:1505-10.
209. Evaluation of impairment/disability secondary to respiratory disorders. *Am Rev Respir Dis* 1986; 133:1205-9.
210. Kanner RE, Renzetti AD, Stanish WM, Barkman HW, Klauber MR. Predictors of survival in subjects with chronic airflow limitation. *Am J Med* 1983; 74:249-55.
211. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1979; 119:895-902.
212. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986; 133:14-20.
213. Kannel WB, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham study. *Am Heart J* 1983; 105:311-5.
214. Kannel WB, Lew EA, Hubert HB, Castelli WP. The value of measuring vital capacity for prognostic purposes. *Trans Assoc Life Insur Med Dir Am* 1981; 64:66-83.
215. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington county, Maryland. *Am Rev Respir Dis* 1989; 140(Suppl):56-63.
216. Foxman B, Higgins ITT, Oh MS. The effects of occupation and smoking on respiratory disease mortality. *Am Rev Respir Dis* 1986; 134:649-52.
217. Annesi I, Kauffmann E. Is respiratory mucus hypersecretion really an innocent disorder? *Am Rev Respir Dis* 1986; 134:688-93.
218. Ortmeier CE, Costello J, Morgan WKC, Swecker S, Peterson M. The mortality of Appalachian coal miners 1963 to 1971. *Arch Environ Health* 1974; 29:67-72.
219. Peto R, Speizer FE, Cochrane AL, *et al*. The relevance in adults of air-flow obstruction, but not of mucous hypersecretion, to mortality from chronic lung disease: results from 20 years of prospective observation. *Am Rev Respir Dis* 1983; 128:491-500.
220. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk of lung cancer. *Ann Intern Med* 1987; 106:512-8.
221. Kuller LH, Ockene J, Meilahn E, Svendsen KH. The relation of forced expiratory volume in one second (FEV₁) to lung cancer mortality in the multiple risk factor intervention trial (MRFIT). *Am J Epidemiol* 1990; 132:235-74.
222. Lebowitz MD, Quackenboss J, Camilli AE, Bronnimann D, Holberg CJ, Boyer B. The epidemiological importance of intraindividual changes in objective pulmonary responses. *Eur J Epidemiol* 1987; 3:390-8.
223. Cochrane GM, Prieto F, Clark TJH. Intrasubject variability of maximal expiratory flow volume curve. *Thorax* 1977; 32:171-6.
224. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy nonsmoking adults. *Am Rev Respir Dis* 1971; 103:57-67.
225. Cherniack RM, Raber MB. Normal standards for ventilatory function using an automated wedge spirometer. *Am Rev Respir Dis* 1972; 106:38-44.
226. Roca J, Sanchis J, Augusti-Vidal A, *et al*. Spirometric reference values from a Mediterranean population. *Bull Eur Physiopathol Respir* 1986; 22: 217-24.
227. Johannsen ZM, Erasmus LD. Clinical spirometry in normal Bantu. *Am Rev Respir Dis* 1968; 97:585-97.
228. Miller GJ, Ashcroft MT, Swan AV, Beadnell HMSG. Ethnic variation in forced expiratory volume and forced vital capacity of African and Indian adults in Guyana. *Am Rev Respir Dis* 1970; 102:979-81.
229. Rossiter CE, Weill H. Ethnic differences in lung function: evidence for proportional differences. *Int J Epidemiol* 1974; 3:55-61.
230. Lap NL, Amandus HE, Hall R, Morgan WKC. Lung volumes and flow rates in black and white subjects. *Thorax* 1974; 29:185-8.
231. Cookson JB, Blake GTW, Faranisi C. Normal values for ventilatory function in Rhodesian Africans. *Br J Dis Chest* 1976; 70:107-11.
232. Patrick JM, Femi-Pearse D. Reference values for FEV₁ and FVC in Nigerian men and women: a graphical summary. *Med J Nigeria* 1976; 6:380-5.
233. Billiet L, Baisier W, Naedts JP. Effet de la taille, et du sexe de l'age sur la capacite de diffusion pulmonaire de l'adulte normal. *J Physiol (Paris)* 1963; 55:199-200.
234. Teculescu DB, Stanescu DC. Lung diffusing capacity. Normal values in male smokers and nonsmokers using the breath-holding technique. *Scand J Respir Dis* 1970; 51:137-49.
235. Van Ganse WF, Ferris BG Jr, Cotes JE. Cigarette smoking and pulmonary diffusing capacity (transfer factor). *Am Rev Respir Dis* 1972; 105: 30-41.
236. Frans A, Stanescu DC, Veriter C, Clerbaux T, Brasseur L. Smoking and pulmonary diffusing capacity. *Scand J Respir Dis* 1975; 56:165-83.
237. Marq M, Minette A. Lung function changes in smokers with normal conventional spirometry. *Am Rev Respir Dis* 1976; 114:723-38.
238. Salorinne Y. Single-breath pulmonary diffusing capacity: reference values and application in connective tissue diseases and in various lung diseases. *Scand J Respir Dis* 1976; 96(Suppl): 1-86.
239. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. *Am Rev Respir Dis* 1981; 123:185-9.
240. Paoletti P, Viegi G, Pistelli G, *et al*. Reference equations for the single-breath diffusing capacity. A cross-sectional analysis and effect of body size and age. *Am Rev Respir Dis* 1985; 132:806-13.
241. Knudson RJ, Kaltborn WT, Knudson DE, Burrows B. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. *Am Rev Respir Dis* 1987; 135:805-11.
242. Roca J, Rodriguez-Roisin R, Cobo E, Burgos F, Perez J, Clausen JL. Single-breath carbon monoxide diffusing capacity prediction equations from a Mediterranean population. *Am Rev Respir Dis* 1990; 141:1026-32.
243. Hall AM, Heywood C, Cotes JE. Lung function in healthy British women. *Thorax* 1979; 34:359-65.
244. Black LF, Offord K, Hyatt RE. Variability in the maximal expiratory flow volume curve in asymptomatic smokers and in nonsmokers. *Am Rev Respir Dis* 1974; 110:282-92.
245. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. *Bull Eur Physiopathol Respir* 1982; 18:419-25.
246. Grimby G, Soderholm B. Spirometric studies in normal subjects. III. Static lung volumes and maximum voluntary ventilation in adults with a note on physical fitness. *Acta Med Scand* 1963; 173:199-206.
247. Reed TE. Caucasian genes in American Negroes. *Science* 1969; 165:762-8.
248. Ghio AJ, Crapo RO, Elliott CG. Reference equations used to predict pulmonary function at institutions with respiratory disease training programs in the United States and Canada: a survey. *Chest* 1990; 97:400-3.
249. Gaensler EA, Smith AA. Attachment for automated single breath diffusing capacity measurement. *Chest* 1973; 63:136-45.